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you can rise above it all. .. 
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EPIGRAPH 
Imagination is more important than knowledge 
Albert Einstein 
CHAPTER I 
INTRODUCTION 
Bone marrow transplantation (BMT) is a complex therapeutic regimen used to treat 
hematologic and oncologic disorders. Autologous, syngeneic and allogeneic bone marrow 
transplants are performed routinely, although allogeneic transplantation is most prevalent due to 
the current sophistication of major histocompatibility complex (MHC) matching and the 
unavailability of syngeneic donors. Graft-vs.-Host Disease (GVHD) is the most frequent 
complication of allogeneic BMT and results in high rates of morbidity as well as mortality. 
GVHD develops when immunocompetent donor lymphoid cells are transplanted into an 
immunocompromised host where alloreactive donor T cells initiate an immune response to 
disparate host major and multiple minor histocompatibility antigens. The knowledge that donor 
T cells initiate GVHD, has prompted many researchers and clinicians to deplete T cell 
populations from the donor inoculum. Although T cell depletion reduces the incidence of 
GVHD, it often abrogates engraftment, promotes leukemic relapse, and exacerbates the 
occurrence of infection. The induction of GVHD may produce a number of deleterious clinical 
complications, yet undefined advantageous components of the disease appear essential to the 
long-term success and increased application of allogeneic BMT. 
This dissertation is focused on the acute form of GVHD that develops within 100 
days post transplant and is characterized by the presence of complex clinical symptoms and 
high mortality rates. Although the development of well-defined skin, liver and G.I. tract 
histopathologies are considered diagnostic of acute GVHD, mortality is most often associated 
with pulmonary complications. GVHD-induced pulmonary complications have been considered 
to be a consequence of viral, fungal and bacterial infection resulting from the deterioration of 
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other organ systems and systemic immune suppression. Previous research has implicated 
interstitial pneumonitis and lymphocytic bronchiolitis/bronchitis as prevalent components of acute 
pulmonary GVHD, but no direct evidence has shown a correlation between the onset of these 
histopathologies or determined whether their presence marks the development of a pulmonary 
syndrome that occurs as a direct result of acute GVHD. The characterization of acute GVHD-
induced pulmonary histopathology has been difficult due to the compounding influence of 
chemotherapeutic agents, immunosuppressive drugs, irradiation and/or overt infection. 
The prevalence and severity of pulmonary complications following allogeneic BMT 
combined with the inconclusive findings of previous studies have led to the fundamental 
question is the lung a target organ of acute GVHD. The hypothesis is that interstitial 
pneumonitis and lymphocytic bronchiolitis/bronchitis occur as a direct result of acute GVHD. 
The primary objectives are to determine the time course, anatomical location, histological 
progression and phenotypic components of acute GVHD-induced pulmonary histopathology. 
The results of these objectives were produced using the adult nonirradiated (DA x LEW) F 1 
hybrid rat in the absence of chemotherapeutic agents, immunosuppressive drugs, and overt 
infection. F1 hybrid rats were injected with 1 x 106 DA parental lymphoid cells/gram body weight 
which produced 100% morbidity and mortality by day 21. Neither syngeneically (F 1 ~ F 1) 
injected nor noninjected F 1 control animals contained any observable or measurable 
histopathology. Consequently, noninjected F 1 animals were used as controls throughout my 
studies. In addition, acute GVHD and control pulmonary tissues did not exhibit evidence of 
bacterial, fungal or viral contamination as determined by light microscopic analysis in 
conjunction with specific tissue and immunohistochemical staining. All GVHD-induced animals 
were killed by ether overdose on days 3, 7, 10, 14 and between 15 - 21 following injection. 
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Prior to the development of flow cytometric analysis (FACS), variations within cell 
populations of histologically and immunohistochemically analyzed tissues were reported in a 
qualitative manner. However, the development and availability of FACS analysis provided a 
way to produce precise quantitative measurements of phenotypic variability. Subsequently, 
FACS analysis remains a widely used method for assessing the immunopathological processes 
occurring within a variety of diseased tissues. 
Chapter Ill details the results provided by FACS analysis of antibody-labeled 
bronchoalveolar lavage (BAL) and collagenase-digested mononuclear cell suspensions obtained 
throughout acute GVHD. A wide panel of mouse anti-rat monoclonal antibodies was used to 
label BAL and collagenase-digested cell suspensions in preparation for FACS analysis. 
Variations within lung weights and cell yields were also determined to assess evidence of 
pulmonary pathogenesis. Although lung weights averaged 2.7g throughout acute GVHD, 
collagenase-digested cell yields increased from 7 .5 x 106 (controls) to 28.2 x 106 (day 14 
GVHD) which corroborated the significant infiltration of mononuclear cells observed in 
subsequent histological studies. BAL cell yields ranged from 2.0 - 11. 7 x 106 (controls) to 2.2 -
51.1 x 106 (day 14 GVHD). FACS analysis conducted using 10 monoclonal antibodies and two 
isotype controls provided reliable labeling, but no consistent trends could be extrapolated from 
the results produced by any two sets of animals. Constraints concerning the time required to 
ensure cell viability and equipment availability made it impossible to assay more than one 
control and one acute GVHD-induced animal at any given time. Overall, FACS analysis of BAL 
and collagenase-digested cell suspensions was incapable of producing results that clearly 
delineated the histopathology induced by acute GVHD. Recently, clinical studies comparing the 
efficacy of BAL to transbronchial biopsies from lungs undergoing GVHD or allograft rejection 
have corroborated my findings. 
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The development and availability of computer-assisted image analysis have made it 
possible to quantify the results obtained from histologic and immunohistochemical studies. 
Consequently, FACS analysis was abandoned in order to conduct histological and 
immunohistochemical analysis on pulmonary tissues. In Chapter IV, H&E-stained paraffin 
sections (4 µm) of whole lobe lung tissues were used to assess the time course, anatomical 
location, and histological progression of the pulmonary histopathology that occurs as a direct 
result of acute GVHD. This study revealed that interstitial pneumonitis and lymphocytic 
bronchiolitis/bronchitis are integral components of acute pulmonary GVHD. The onset of 
interstitial pneumonitis (IP) was characterized by the coalescence of infiltrated perivascular and 
alveolar mononuclear cells after dissolution of the adventitial limiting plate. Lymphocytic 
bronchiolitis/bronchitis (LB) developed just prior to the dissemination of perivascular infiltrates. 
Furthermore, the sequential development of acute GVHD-induced IP and LB duplicated the 
histopathology of lung allograft rejection. This study defined the lung as an important target 
organ of acute GVHD. 
The perivascular infiltrates of IP are the most prominent and easily quantified 
histological feature of acute GVHD. Therefore, Chapter V describes the phenotypic 
components of perivascular mononuclear infiltrates throughout acute GVHD. A streptavidin-
biotin method of immunohistochemical analysis was employed using 10 mouse anti-rat 
monoclonal antibodies on frozen whole lobe lung sections (4 µm). The density of antibody 
labeling (volume density) was quantified using computer-assisted image analysis. Results 
determined that the process of perivascular infiltration was a biphasic response characterized 
first by the influx of ED1+, OX8+, and W3/25+ populations by day 7, and then OX41+, W3/13+, 
and OX19/52+ populations by day 14. OX6+ mononuclear cells were present within the 
perivascular spaces of control and GVHD animals at all time points tested. OX12, .OX39 and 
MOM/3F12/F2 were not quantifiable within perivascular spaces at any time point tested. 
This dissertation has determined that the lung is an important target organ of acute 
GVHD. Data have been produced to demonstrate that: (1) FAGS analysis of BAL cell 
suspensions may be able to suggest an ongoing immune process, but in the absence of 
transbronchial biopsy this method is incapable of determining the onset or progression of acute 
pulmonary GVHD prior to clinical symptoms occurring from the significant deterioration of 
normal pulmonary structure, (2) IP and LB occur as a direct result of acute GVHD, (3) IP 
develops prior to LB and is produced by the coalescence of perivascular and alveolar 
mononuclear cell infiltrates, (4) acute GVHD-induced IP and LB duplicate the histopathology of 
lung allograft rejection, and (5) the process of perivascular infiltration is characterized by a 
biphasic influx of class W, T cell and macrophage populations. 
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CHAPTER II 
REVIEW OF RELATED LITERATURE 
Historical Overview 
Bone Marrow Transplantation 
In 1891, Brown-Sequard and d'Arsonaval (quoted by Quine 1896) orally 
administered bone marrow to patients with leukemia-induced anemia in the first recorded 
attempts to use marrow as a therapeutic measure. The oral administration of bone marrow 
proved unsuccessful and clinical attempts were curtailed until 1937 when Schretzenmayr 
prepared fresh intramuscular injections of autologous or allogeneic bone marrow to treat anemic 
patients with malaria or helminthic infections (Schretzenmayr 1937). However, by 1939 
intramuscular injections were known to be as unsuccessful as oral administration. These 
findings led Rasjek (according to Migdalska 1958) to inject marrow directly within the 
intramedullary cavity as treatment for patients with lymphatic leukemia and pernicious anemia 
(Migdalska 1958). Although Rasjek's attempts were not reported to be successful, Morrison 
and Samwick effectively treated a patient with aplastic anemia by modifying Rasjek's 
intramedullary protocol to administer three infusions of bone marrow that had been aspirated 
from the patient's brother (Morrison and Samwick 1940). While the intramedullary protocol 
appeared promising, Osgood, Riddle and Mathews refined the procedure by intravenously 
injecting fresh bone marrow into patient's with aplastic anemia (Osgood, Riddle, Mathews 1939). 
Subsequently, the intravenous protocol for administration of bone marrow was accepted as the 
optimal method for undertaking hematopoietic reconstitution and currently remains standard 
practice for allogeneic bone marrow transplantation (BMT). 
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Irradiation 
The ability to produce hematopoietic chimerism following lethal doses of total body 
irradiation (TBI) was discovered between 1945 - 1949 as a result of government research on 
the effects of atomic warfare, and became the foundation of modern bone marrow 
transplantation. In 1951, Lorenz et al. discovered that lethally irradiated mice and guinea pigs 
were protected from certain death by the parenteral administration of syngeneic marrow (Lorenz 
et al. 1951). Subsequent research determined that allogeneic and xenogeneic bone marrow cell 
injections were also therapeutically effective in prolonging survival from 20 - 30 days (Lorenz, 
Congdon and Uphoff 1952, Lorenz and Congdon 1954). By 1956, several other studies used a 
variety of genetic markers to demonstrate that the colonization of host marrow by donor cells 
provided a protective effect against lethal irradiation (Lindsley, Odel and Tausche 1955, Ford et 
al. 1956, Mitchison 1956, Nowell et al. 1956). As a result of host marrow reconstitution by 
donor cells, Ford et al. introduced the term "radiation chimera" to describe an animal that 
carries a foreign hematopoietic system as a result of lethal irradiation followed by the 
transplantation of hematopoietic cells from another animal (Ford et al. 1956). The most 
effective means of producing the chimeric state was acknowledged to be the intravenous 
administration of bone marrow cells following irradiation. The number of allogeneic cells 
required to produce optimal hematopoietic chimerism was reported to be 10 - 80 times the 
number of syngeneic cells required (van Bekkum and Vos 1957). 
Chimeric studies demonstrating that hematopoietic reconstitution could be achieved 
in an irradiated host following the intravenous administration of bone marrow cells were 
instrumental to the incorporation of irradiation as a pre-transplant regimen in contemporary 
allogeneic BMT. In 1957, Thomas et al. were the first to describe transient engraftment in 
humans by intravenously infusing large amounts of marrow following irradiation and 
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chemotherapy (Thomas et al. 1957). By 1959, Mathe et al. attempted to rescue six human 
victims of an irradiation accident using allogeneic marrow, and in 1963 reported the first long-
term survival of a 26-year-old leukemic patient that displayed evidence of complete engraftment 
(Mathe et al. 1959, 1963). This patient suffered from acute as well as chronic GVHD, but 
eventually died without any evidence of leukemia 20 months post transplant from varicella 
encephalitis (Mathe 1963). Although these early recorded efforts at allogeneic BMT following 
irradiation became the foundation for modern clinical protocols, attempts at engraftment were 
usually unsuccessful because they occurred prior to the concepts of histocompatibility and 
immunosuppression. 
Major Histocompatibility Complex 
Immunological identity of self versus foreign tissues is based on the expression of 
cell-surface proteins known as major histocompatibility complex (MHC) antigens. Disparate 
major and minor histocompatibility antigens expressed on cells or tissues transferred from one 
patient to another are normally recognized by the recipient, leading to rejection in a host-vs.-
graft reaction. However, immunologically competent cells within the graft can also produce an 
immune response in the opposite direction, producing a Graft-vs.-Host Reaction (GVHR). MHC 
major and minor antigenic disparity between recipient and donor are the most important risk 
factors for the induction of graft failure and Graft-vs.-Host Disease (GVHD) (Reviewed in 
Ferrara and Deeg 1991). 
Dausset discovered the human MHC, termed human leukocyte antigen (HLA) in the 
mid-1950's (Dausset 1958). Delineation of the MHC complex between the late 1960's and early 
1970's, provided the knowledge required to immunologically select a bone marrow donor and 
facilitate the future success of allogeneic BMT. During the early 1970's, MHC class I 
molecules, constitutively expressed by most tissues, became known as the major 
transplantation antigens. In contrast, MHC class II molecules were not recognized as the 
critical components of antigen recognition and alloreactive responses because contemporary 
serological assays had not been refined (Reviewed in Krensky et al. 1990). Consequently, it 
was not until 197 4, when Zinkernagel and Doherty discovered that T cell recognition required 
both foreign antigen and the body's own MHC complex (Zinkernagel and Doherty, 1974). The 
de nova and upregulated expression of MHC class II antigens within host cutaneous, intestinal 
and hepatic compartments is considered to be a diagnostic component of acute GVHD (see 
Target Organs, p. 24). MHC compatibility between donor and host remains essential to the 
long-term survival of patients following allogeneic BMT, and the continued implementation of 
BMT as a therapeutic option. 
Cytoreductive Therapy 
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Pre-transplant conditioning is used to: (1) promote graft survival by inducing 
immunosuppression through the elimination of host immunocompetent cells, (2) provide an anti-
cancer effect, and (3) induce myeloablation to provide "room" for grafted cells. These goals are 
most often achieved by irradiation and the administration of chemotherapeutic agents 
(summarized up to 1963 by van Bekkum and de Vries 1967). In 1960, Beilby et al. provided 
the first evidence that chemotherapy could be used to perform allogeneic transplants (Beilby et 
al. 1960). A patient with Hodgkin's disease developed severe marrow hypoplasia after receiving 
aminochlorambucil, but an infusion of bone marrow from the patient's sister resulted in a 24% 
increase of donor erythrocytes 6 months post transplant. 
By 1970, a series of animal and clinical studies developed a rationale for using 
cyclophosphamide (CY) as a preparative regimen for human allogeneic BMT (Santos, Owens 
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and Sensenbrenner 1964; Santos et al. 1970). Further murine and rat studies demonstrated the 
combined efficacy of busulphan (BU) and CY during human allogeneic BMT (Santos 1966a, b; 
Santos and Hagshenass 1968; Sensenbrenner et al. 1968; Santos and Tutschka 197 4a, b; 
Tutschka and Santos 1975a, b; Tutschka and Santos 1977). Cyclophosphamide appeared to 
be an excellent immunosuppressive agent with anti-tumor properties, but did not appear capable 
of removing enough host cells to make "room" for the graft. In contrast, BU was lacking 
immunosuppressive capabilities but had excellent anti-tumor properties and appeared to remove 
enough cells to provide "room" for engraftment. The concept of "room" referred to the physical 
space required for the accommodation of transplanted cells and the non-immunological factors 
necessary to promote engraftment (Santos 1974). The use of cytoreductive chemotherapeutic 
drugs, such as BU and CY, remains a crucial part of the allogeneic BMT protocol. 
Graft-vs.-Host Reaction. Secondary Disease. Runt Disease 
The Graft-vs.-Host reaction was first described by James B. Murphy in 1916, fifteen 
years after Brown-Sequard and d'Arsonaval attempted to use bone marrow to cure leukemia-
induced anemia (Murphy 1916, Quine 1896). Murphy inoculated the chorioallantoic membranes 
of 7-day-old chicken embryos with fragments of spleen and bone marrow obtained from adult 
chicken donors. The inoculation induced a marked host splenomegaly as well as the 
development of varying sized whitish nodules on spleen and chorioallantoic membranes. 
Murphy attributed this immunologic process to stimulation of the host's spleen and the 
subsequent proliferation of host leukocytic elements in additional tissue sites (Murphy 1916). 
Murphy's preliminary observations were confirmed and extended by Danchakoff through an 
extensive histological analysis of the effects produced by grafting adult spleen cells to 
chorioallantoic membrane (Danchakoff 1918, 1920). She observed that the capacity to 
stimulate host mesenchymal tissues was confined to spleen, liver and marrow cells obtained 
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from a donor of the same species. Danchakoff favored the belief that proliferation of the host's 
spleen was induced by the blood-borne products of metabolism produced from viable 
transplanted cells. The observations by Murphy and Danchakoff formulated the definition of 
GVHR. 
In 1955, Barnes and Loutit were first to report the development of an immunologic 
syndrome with lethal consequences that appeared unrelated to the primary cause of disease, 
termed "secondary disease" (Barnes and Loutit 1955). Lethally irradiated CBA mice given 
syngeneic spleen cells survived radiation injury. However, 9 out of 16 lethally irradiated CBA 
mice injected with A strain spleen cells died between 30 - 100 days post transplantation. 
Although the mice were recovering from radiation injury and marrow aplasia, an injection of 
allogeneic marrow induced mortality from a secondary disease that was characterized by severe 
diarrhea, weight loss, skin lesions and liver abnormalities (Barnes and Loutit 1955, Cohen, Vos 
and van Bekkum 1957). Trentin also demonstrated that mice given syngeneic bone marrow 
after TBI were provided with long-lasting protection and a minimum of complications (Trentin 
1956). While the injection of allogeneic marrow into lethally irradiated mice resulted in weight 
loss, diarrhea, skin lesions and significant mortality between 20 - 100 days. Subsequently, the 
induction of this "secondary disease" syndrome was confirmed in rats, dogs, primates and man 
(studies compiled by van Bekkum and de Vries 1967). The severity and accelerated 
development of secondary disease was induced by increasing the number of lymphoid cells 
injected with bone marrow (Santos and Cole 1958). These observations provided evidence to 
support future acknowledgements of a GVHD mechanism. 
In 1956, Billingham and Brent described a similar "secondary disease" as "runt 
disease" after conducting studies on the induction of tolerance using murine skin homografts 
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(Billingham and Brent 1957, 1959). Newborn host CBA mice were intravenously injected with a 
spleen cell suspension obtained from an A strain murine donor. Mortality was low in the 
neonatally inoculated hosts and most recipients developed into normal adults tolerant of A skin. 
Yet, post-mortem examination revealed hypoplasia in most lymphoid organs. In other murine 
strain combinations, recipient mice stopped growing, became emaciated and frequently suffered 
from diarrhea. Although most of the affected mice died within a few days, some survived for a 
month or two in a chronically ill state. These mice were characterized by retarded growth and 
development, sparse abnormal-looking fur, varying degrees of lymphatic hypoplasia, 
erythematous desquamating dermatitis that produced a mincing gait, and focal necrosis of 
hepatic cells (Billingham and Brent 1957, 1959). 
Three specific lines of evidence suggested that the "runt disease" described by 
Billingham and Brent resulted from a graft-vs.-host reaction: (1) the severity of the disease was 
directly proportional to the genetic disparity between donor and host strains, (2) the severity of 
the disease was heightened and accelerated if the spleen cells used in the donor innoculum 
were previously sensitized against the antigens of the intended recipient, and (3) the disease 
did not develop if spleen cells from an F1 hybrid donor were injected into parental strain 
newborn mice (Billingham and Brent 1957,1959). Both secondary disease and runt disease 
appeared to be the result of immunologically competent cells within the donor innoculum 
reacting against foreign transplantation (MHC) antigens of the immunologically immature or 
immunocompromised host (Billingham and Brent 1957, 1959). Subsequent studies confirmed 
that secondary disease was immunologically equivalent to runt disease and both were 
eventually shown to be GVHD. 
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Graft-vs.-Host Disease 
The most life-threatening complication of allogeneic BMT is Graft-vs.-Host Disease 
(GVHD}, which occurs in more than 80% of unrelated HLA-matched transplants with a 50% 
mortality rate. By 1966, several reports documenting the development of GVHD led Billingham 
to formulate the requirements for induction of GVHD: (1) the graft must contain immunologically 
competent cells, (2) the host must express tissue antigens that are absent in the graft donor, 
appear foreign to the donor, and are capable of antigenic stimulation, and (3) the host must be 
incapable of mounting an effective immunologic response against the donor graft (Billingham 
1966-67). 
By the early 1960's, Medawar had postulated that small lymphocytes were the 
immunologically competent donor cells necessary to induce GVHD, and Gowans was the first to 
prove this hypothesis (Medawar 1963, Gowans 1962). Gowans demonstrated that a 
suspension of thoracic duct lymphocytes, depleted of large lymphocytes by incubation overnight 
at 37° C, retained GVHD reactivity when injected into adult F1 hybrid rats (Gowans 1962). 
McGregor expounded on Gowan's data by showing that bone marrow could generate the 
immunologically competent small lymphocytes capable of initiating a lethal graft-vs.-host 
reaction (McGregor 1968). In addition, McGregor was able to show that although bone marrow 
cells were incapable of directly producing GVHD, some bone marrow stem cells can become 
GVHD-inducing T cells after thymic influence. Subsequently, Owens and Santos provided 
quantitative data to show that various tissues displayed a greater ability to produce lethal GVHD 
in the cyclophosphamide mouse than others: peripheral blood > lymph node > spleen > marrow 
(Owens and Santos 1968). Cells isolated from the thymus were relatively inactive. These data 
extended and confirmed the earlier observations of Billingham and Silvers (Billingham and 
Silvers 1962). 
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A consistent manifestation of GVHD in all tested species was shown to be 
splenomegaly, which peaked 6 - 10 days after the injection of immunocompetent donor cells, 
and provided a quantitative assay to assess the severity of GVHD (Simonsen 1962). In 1962, 
Simonsen developed the spleen index assay to determine the degree of splenomegaly. 
Absolute spleen weights of recipient animals were compared to uninjected littermate controls, 
and relative spleen weights were determined by comparing spleen/body weight ratios. Spleen 
index was calculated for each recipient animal by dividing its relative spleen weight by the 
relative spleen weight for control littermates. An index of 1.0 indicated no change in spleen 
weight, whereas an index of 2.0 determined a doubling of spleen weight. The spleen index 
assay remains the most commonly used parameter to assess the development of GVHD in 
experimental models. 
The most severe form of acute GVHD occurs when genetic disparity exists 
between donor and host, and a large number of mature T lymphoid cells are included in the 
donor inoculum. Evidence that GVHD is directly proportional to the presence of donor Thy 1 + T 
cells was demonstrated by pretreating parental strain lymphoid cells with anti-Thy 1+ antibody 
plus complement in H-2 different neonatal F 1 mice or adult irradiated F 1 mice (Cantor 1972, 
Sprent, von Boehmer and Nabholz 1975). Subsequently, many laboratories demonstrated that 
GVHD produced across MHC disparity was caused by mature T cells (Tyan 1973, Trentin and 
Judd 1973, Rodt, Thierfelder and Eulitz 1974, Muller-Ruchholtz, Wottge and Muller-Hermelink 
1976, Onoe, Fernandes and Good 1980, Vallera et al. 1981). 
Additional studies have indicated that lethal GVHD in irradiated adult mice can be 
elicited by multiple minor histocompatibility antigen differences as well as full MHC disparity 
(Korngold and Sprent 1978, Halle-Pannenko et al. 1978, Hamilton, Bevan and Parkman 1981, 
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O'kunewick et al. 1982). Korngold and Sprent treated marrow cells with anti-Thy 1.2 antibody 
and complement to deplete mature T cell populations while leaving pre-T cells intact. The 
transplantation of T-cell-depleted 810.BR marrow into allogeneic irradiated recipients across 
only minor histocompatibility differences failed to cause GVHD. Consequently, this study 
demonstrated that GVHD to minor antigens is produced by mature T cells contaminating donor 
marrow (Korngold and Sprent 1978). 
The subset of mature T cell required to produce GVHD was determined by adding 
separate T-cell populations to the donor bone marrow. The first study to determine the role of T 
cell subsets in producing lethal GVHD across a full MHC barrier was conducted in rats (Mason 
1981 ). Depletion of OX8+ (Lyt-2+) (cytotoxic T) donor cells produced a population of W3/25+ 
(helper T) cells that were very potent inducers of lethal GVHD. Although the transfer of purified 
OX8+ cells produced a weaker but eventually lethal GVHD. 
In a murine model, highly purified L3T4+ and Lyt-2+ T cell populations were 
produced using antibody combined with complement depletion and positive panning on 
antibody-coated plates. These purified populations indicated that both subsets were active 
during the induction of GVHD (Sprent and Schaefer 1985). Purified Lyt-2+ T cells were fully 
capable of producing GVHD in murine models of allelic or mutant MHC class I differences 
(Korngold and Sprent 1985, Sprent et al. 1986). Additional studies using different strain 
combinations showed that Ly-2+ cells consistently produced GVHD to minor histocompatibility 
antigens, while L3T4+ were able to induce GVHD in only a minority of the same strain 
combinations. Consequently, Ly-2+ T cells were characterized as the only mediators of anti-
class I GVHD, and L3T4+ T cells were characterized as the initiators of anti-class II GVHD. 
Both populations were capable of inducing GVHD in murine strain combinations with full H-2 
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genetic disparity (Korngold and Sprent 1983, 1987). 
Further murine and human studies using MHC-matched marrow demonstrated that 
cytotoxic T cells directed against minor histocompatibility antigens were the initiators of GVHD. 
The identification of disparate minor histocompatibility antigens required MHC (H-2) priming and 
were shown to be MHC-restricted (Bevan 1975, Hamilton et al. 1981). Cytotoxic T cells 
directed at minor histocompatibility antigens were also detected in patients with acute GVHD 
following BMT (Goulmy et al. 1984). These T cells were cloned and used as typing reagents to 
identify 4 minor histocompatibility antigens. Data compiled from rat, murine and human studies 
have established that specific T cell subsets initiate the development of acute GVHD in 
response to disparate major and/or minor histocompatibility antigens. 
I mmunosuppression 
lmmunosuppression is required to reduce the occurrence and severity of acute 
GVHD in all patients undergoing allogeneic BMT. Common methods of immunosuppression 
include the use of cyclosporine A (CsA) and methotrexate (MTX), as well as T cell depletion of 
the donor inoculum. Since donor T lymphocytes are acknowledged to initiate GVHD, 
immunosuppression is designed to block the activation of T cells or eliminate them. 
Cyclosporine A. Cyclosporine A, a fungal metabolite, was introduced as an 
immunosuppressive drug in the 1970's. Initial reports suggested that established acute GVHD 
was lessened after the administration of CsA, but additional studies demonstrated that 
symptomatic acute GVHD did not respond to CsA administration (Powles et al. 1980, Tutschka 
et al. 1983). In contrast, CsA prevented the development of acute GVHD after allogeneic BMT 
in rats prepared with TBI or CY, and acute GVHD did not appear when the drug was 
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discontinued (Tutschka et al. 1979). In addition, acute GVHD may appear after the withdrawal 
of immunosuppressive drugs, such as CsA (Powles et al. 1980). 
The mechanism of CsA is still not completely understood, but the drug appears to 
inhibit T cell activation. CsA has inhibited the proliferative response to: (1) concanavalin A in 
murine, rat and human studies (Leoni, Garcia and Allison 1978, Burckhardt and Guggenheim 
1979, White et al. 1979, Larsson 1980), (2) to phytohemagglutinin in porcine, rat and human 
models (Leoni, Garcia and Allison 1978, Burckhardt and Guggenheim 1979, White et al. 1979,) 
and (3) pokeweed mitogen in humans (Leoni, Garcia and Allison 1978). Several studies have 
indicated that CsA inhibits the synthesis of interleukin-2, interleukin-2r, interleukin-3, 
interleukin-4, interferon-gamma, tumor necrosis factor-alpha, and potentially interleukin-1 mRNA 
at the transcriptional level (Elliot et al. 1984, Granelli-Piperno, Inaba and Steinman 1984, 
Granelli-Piperno, Andrus and Steinman 1986, Granelli-Piperno, Keane and Steinman 1988, 
Goldfeld et al. 1993). In addition to remarkable immunosuppressive effects, CsA appeared to 
promote a faster rate of engraftment and decreased the occurrence of mucositis (Atkinson et al 
1983). Although the use of CsA is limited by the induction of severe nephrotoxicity (Barrett et 
al. 1982). 
Methotrexate. Methotrexate is a folic acid antagonist with immunosuppressive and 
anti-neoplastic activity that may prevents the division and clonal expansion of activated T cells 
by deactivating activated macrophages or affecting the function of adenosine receptors. In 
1970, Storb observed that the administration of MTX to irradiated dogs following syngeneic 
marrow 90% induced survival without the production of acute GVHD (Storb et al. 1970). In 
contrast, dogs that did not receive MTX post-transplant developed a 55% incidence of acute 
GVHD and underwent a 45% decrease in survival rate. As a result of these studies, clinical. 
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trails were conducted to determine the efficacy of MTX administration following BMT (Sullivan et 
al. 1986). Patients that did not receive MTX developed hyperacute GVHD with exacerbated 
infectious complications and poor graft function. 
In 1983, Deeg et al. reported that there was no statistical difference between 
the immunosuppressive capabilities of CsA and MTX as compared to the development of GVHD 
or prolonged survival (Deeg et al. 1983). However, the survival rate in dogs following allogeneic 
BMT was increased from 6% with either CsA or MTX to 35% when the drugs were combined 
(Deeg et al. 1982). Subsequently, Storb et al. conducted a prospective randomized study in 48 
patients with severe aplastic anemia to compare the single or combined use of CsA and MTX 
(Storb et al. 1986 a). Results showed that a combination of CsA/MTX significantly reduced the 
incidence of severe acute GVHD to 18% as compared to 53% for CsA or MTX alone. Similar 
results were obtained in patients with acute lymphoblastic leukemia, acute nonlymphoblastic 
leukemia, chronic myelocytic leukemia, or chronic granulocytic leukemia (Storb et al. 1986 b, 
1988, 1989). Consequently, the combination of CsA and short-course MTX is considered 
standard protocol for acute GVHD prophylaxis following allogeneic BMT. 
T cell depletion. In addition to post- transplant immunosuppression, the pre-
transplant depletion of T cells from the donor inoculum has also been shown to prevent the 
development of acute GVHD. This concept worked well in murine studies conducted by 
Korngold and Sprent, and as a result several clinical transplantation centers incorporated a 
variety of techniques to eliminate T cells throughout the 1980's (Korngold and Sprent 1978). 
The techniques developed for T cell depletion included using anti-T-cell antibodies alone, in 
combination with heterologous or homologous complement, conjugated to immunotoxins, or 
combined with immunomagnetic beads (Vallera et al. 1981, Prentice et al. 1984, M;:irtin et al. 
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1985, Apperley et al. 1986, Mitsuyasu et al. 1986, Atkinson et al. 1987, Filipovich et al. 1987, 
Vartdal et al. 1987). In addition, counterflow centrifugal elutriation, density fractionation, and 
differential agglutination with soybean lectin followed by rosetting with sheep erythrocytes were 
all T cell depleting methods that did not rely on the use of antibodies (Reisner et al 1981, 
O'Reilly et al. 1985, DeWitte et al. 1986, Lowenberg et al. 1986, Wagner et al. 1988). 
The data compiled from clinical centers confirmed that the occurrence and severity 
of GVHD were significantly reduced using T-cell depleted allogeneic bone marrow transplants. 
However, these T-cell depleted transplants produced an increase in graft failure as well as 
leukemic relapse, and delayed immune reconstitution ( Prentice et al. 1982, Filipovich et al. 
1984, Martin et al. 1985, 1988, O'Reilly et al. 1985, Trigg et al. 1985, Henslee et al. 1987, 
Maraninchi et al. 1987). The primary disadvantage of T-cell depleted marrow transplants in 
patients preconditioned with TBI was the severe prolonged immunoincompetence that resulted 
in a heightened susceptibility to opportunistic infection (Weiner and Dicke 1987). Eventually, it 
became apparent that the development of acute GVHD had a positive impact on the rate of 
engraftment and the elimination of malignant cells. These findings have compounded the 
necessity for defining the complex immunologic phenomenon of acute GVHD. 
Historical Summary 
The number of allogeneic BMT's performed worldwide increased exponentially 
during the 1980's. In 1990 alone, over 4000 allogeneic transplants were estimated to have 
been completed. The standard contemporary protocol for conducting allogeneic BMT, requires 
the use of supralethal chemotherapeutic drugs and radiation in an attempt to "cure" the tumor-
bearing host, which is followed by "immunologic rescue" from clinically-induced hematopoietic 
failure through the adoptive transfer of marrow stem cells from a healthy MHC-matched donor. 
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Bone marrow transplantation is now considered to be an accepted therapeutic option for 
patients with chronic myelogenous leukemia, aplastic anemia, severe combined 
immunodeficiency and oncologic disorders that are resistant to previous therapies. Patients 
under 40 who have an HLA-identical sibling donor and are transplanted for chronic 
myelogenous leukemia while in the chronic phase of disease, or those with acute lymphoblastic 
leukemia in remission are the most likely to enjoy disease-free survival. The establishment of 
an International Bone Marrow-Donor Registry has increased the availability of HLA-matched 
marrow from unrelated donors. However, the increased use of MHC-matched unrelated 
allogeneic BMT has focused attention on the immunobiologic complexities and consequences of 
GVHD, which remains the primary immunologic complication and leading cause of death 
following allogeneic BMT. 
Acute Graft-versus-Host Disease 
Experimental Models 
Murine vs. rat. The use of animal models has been critical to defining and 
understanding the pathogenesis as well as pathogenetics of GVHD. Although canine, porcine, 
rabbit, hamster, guinea pig, monkey, murine, rat and human models have been used to study 
the immunopathogenesis of GVHD, murine and rat models are the most extensively used. 
Proponents of the murine model rely on the availability of numerous inbred strains that allow for 
control over genetic variables. In addition, there is a wide variety of cellular and molecular 
probes readily available. In contrast, proponents of the rat model believe that the rat's 
intermediate size provides technical advantages over the murine model (Gill et al. 1989). 
Although there are fewer inbred strains available, the rat can provide large amounts of cells as 
well as serum, and relatively large internal organs can easily be assessed for histological and 
immunohistochemical studies. 
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Lewis/SN and Lewis/DA rat strain combinations are considered to be optimal rodent 
models for GVHD experimentation. In 1966, Elkins and Palm demonstrated that only rats with 
antigenic variability at the Ag-8 locus of the major histocompatibility complex can elicit graft-
versus-host reactions using spleen cells from unsensitized donors (Elkins and Palm 1966). 
Lewis, BN and DA rat strains all contain variant alleles of the Ag-8 locus, and have at least one 
locus closely linked to the Ag-8 site that codes for minor alloantigens (Marshak et al. 1977). In 
1975, Atkins and Ford estimated the proportion of rat lymphocytes responsive to Ag-8 antigens 
in the GVH reaction (Atkins and Ford 1975). Radioactively labeled parental and F 1 thoracic 
duct lymphocytes were intravenously injected into F 1 rats. The amount of labeled cells retained 
within recipient spleens allowed Atkins and Ford to calculate that approximately 12% of parental 
lymphocytes reacted to the products of one Ag-8 haplotype. It was also estimated that 4.5-
6.0% of donor T cells were specifically responsive to the recipient's Ag-8 antigens. Additional 
studies using anti-idiotypic serum in Lewis and DA rats confirmed major and minor 
histocompatibility antigen disparity at the Ag-8 locus (Binz and Wigzell 1975). Consequently, 
the Lewis/DA strain combination was used throughout this dissertation to investigate the 
immunohistopathology of acute GVHD. 
Irradiated vs. parental-+ F1 hybrid. The two most common experimental models 
used to induce GVHD incorporate total body irradiation and the intravenous injection of parental 
lymphoid cells into F 1 (P -+ F 1 ) mice or rats. The irradiated protocol produces the classic 
radiation chimera by destroying the recipient's marrow stem cells and immune system prior to 
the intravenous injection of donor lymphoid cells. In the radiation chimera, weight loss and 
mortality are the primary assays used to determine the onset and severity of GVHD. Although, 
the development of well-defined histopathologies within lymphoid and nonlymphoid organs are 
also used to assess the severity of GVHD (Rappaport et al. 1979). The irradiated model is 
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used extensively because it is believed to duplicate the clinical setting. 
In the P ~ F1 model, the F1 host is tolerant of parental donor antigens and can not 
reject the injected donor cells. In contrast, the donor cells are stimulated by alloantigens 
expressed on F1 host cells which induces GVHD. The injection of more than 100 x 106 donor 
lymphoid cells into F1 animals produces a GVHD that strongly resembles the disease induced in 
irradiated animals. The injection of fewer than 20 - 60 x 106 donor lymphoid cells into F1 
animals induces a weak GVHD that does not produce wasting or skin lesions. In the (P~ F1 ) 
model, the primary assays used to determine the onset and severity of GVHD are: (1) spleen 
index to determine the degree of splenomegaly (Simonsen 1962), (2) developing histopathology 
within GVHD target organs (see Target Organs p. 24), and (3) immunosuppression (Shearer 
and Pollisson 1980). Spleen index is used and reflects the donor-cell induced recruitment of 
host cells (Howard, Michie and Simonsen 1961, Fox 1962, Elie and Lapp 1977). 
lmmunosuppressive assays are used often because the F1 immune system is intact prior to the 
injection of parental lymphocytes. The P~ F1 model makes it possible to study ongoing 
immunopathogenesis in direct relationship to the development of acute GVHD. 
In either the irradiated or P~ F1 modes, it is disparity between major and minor 
histocompatibility antigens that determines the severity of graft-versus-host immune dysfunction 
(Rolink, Pals and Gleichmann 1983, Shearer and Levy 1983, Moser, Sharrow and Shearer 
1988, Moser et al. 1987). Acute GVHD produced across disparate class I and II MHC antigens 
is characterized by the severe immune deficiency of T- and 8-cell functions, the direct attack of 
donor cells on lymphohematopoietic tissues, and a reconstitution of the lymphohematopoietic 
system with donor-derived cells ( van Eleven et al. 1981, Rolink et al. 1982, Via, Sharrow and 
Shearer 1987, Knobloch and Dennert 1988, Moser, Sharrow and Shearer 1988). Class II 
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disparity is characterized by the limited engraftment of donor cells, limited T-cell functional 
deficiency, polyclonal B-cell activation and production of autoantibodies (van Eleven et al. 1981, 
Rolink et al. 1982, van Rappard-van der Veen, Rolink and Gleichmann 1982, Rolink, Pals and 
Gleichmann 1983, Via, Sharrow and Shearer 1987, Knobloch and Dennert 1988). Neither class 
I nor minor histocompatibility disparity can produce an acute GVHD in the P ~ F1 model (Rolink, 
Pals and Gleichmann 1983, Moser, Sharrow and Shearer 1988, Shearer and Levy 1983). 
Onset and Clinical Grading of GVHD 
In both animal and human models, GVHD exists in acute and chronic forms. Acute 
GVHD usually develops within the first 100 days post transplantation and often precedes the 
onset of chronic GVHD in the following ways: (1) acute phase disease is not followed by the 
chronic form, (2) acute disease may gradually progress into the chronic phase (progressive 
GVHD), (3) acute disease may appear in remission for a length of time followed by the sudden 
onset of chronic disease (quiescent GVHD), or (4) chronic GVHD may appear in the absence of 
acute phase disease (de nova GVHD) (Sullivan 1981). The onset of GVHD is usually preceded 
by signs of engraftment, but occasionally GVHD may appear in the complete absence of 
engraftment (empty marrow, low peripheral blood cell counts). Consequently, clinical and 
histological characteristics are more definitive parameters of hematopoietic reconstitution than 
the onset of acute GVHD. 
In 1974, Glucksberg et al. established a clinical grading system to assess the 
development of acute GVHD based on pathological and clinical parameters (Glucksberg et al. 
1974). This grading system remains instrumental to the clinical management of allogeneic BMT 
patients, and classifies the severity of clinical symptoms from grades I - IV. Grade I consists of 
only skin pathology. The onset of extensive skin pathology, liver or intestinal tract symptoms, 
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and impairment of clinical performance, either alone or in any combination, advances the grade 
of acute GVHD from II - IV. Overall, the grade of acute GVHD profoundly affects a patient's 
prognosis following allogeneic BMT. 
Taraet Organs 
Cutaneous GVHD. Skin, intestinal tract, and liver are the main target organs of 
acute GVHD. Cutaneous symptoms signal the onset of acute GVHD, and include itching, pain 
upon pressure, and retroauricular as well as palmoplantar erythema. More is known about the 
cutaneous histopathology of acute GVHD than any other target organ pathology because 
frequent biopsies can be taken to assess temporal changes throughout the disease without 
producing serious morbidity. 
The clinical and histological grading of acute cutaneous GVHD have been classified 
as: (1) Grade I - Macularpapular rash on less than 25% of total body surfaces with basal cell 
vacuolization, (2) Grade II - Macularpapular rash on more than 25% of total body surfaces with 
basal cell vacuolization, and single necrotic keratinocytes that appear as mummified cells 
adjacent to satellite lymphocytes, (3) Grade Ill - Erythroderma with subepidermal clefts and 
numerous keratinocytes, and (4) Grade IV - Toxic epidermal necrolysis with necrosis of the 
entire epidermis and complete desquamation (Glucksberg et al. 1974). Consequently, epithelial 
necrosis is considered to be diagnostic of acute GVHD (Sale et al. 1977). In spite of the well-
defined grading system, signs of acute cutaneous GVHD are difficult to distinguish from viral 
infections, and cytoreductive drugs, immunosuppressive therapy, allergic antibiotic reactions, or 
radiation damage (Sale et al. 1977). 
Throughout the 1980's, several studies observed that class II MHC antigens, 
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normally found only on dendritic Langerhans cells, were expressed on keratinocytes throughout 
acute GVHD (Breathnach and Katz 1983, Vole-Platzer et al. 1988). In 1982, Lampert et al. 
were among the first to assess the expression of class II MHC antigens and determine the 
phenotype of lymphoid cells present within epidermal infiltrates (Lampert et al. 1982). 
lmmunohistochemical analysis of skin biopsies taken from acute GVHD patients provided 
evidence that class II expression was observed on keratinocytes and dermal macrophages, 
while the population of dendritic Langerhans cells was significantly reduced. OKT8+ (cytotoxic 
T) cells were the predominant phenotype within lymphoid infiltrates. These observations were 
later confirmed by Lever et al. during immunohistochemical studies on skin biopsies taken from 
acute GVHD patients (Lever et al. 1986). Furthermore, the class II antigen expressed on 
keratinocytes was shown to be synthesized by the keratinocytes themselves and not derived 
from donor lymphocytes or absorbed from host Langerhans cells (Breathnach and Katz 1983). 
By 1986, several studies attempted to define the role of T cells observed within 
cutaneous lesions and establish their proximity to class W keratinocytes. The expression of 
class II on keratinocytes appeared directly related to the presence of lymphocytic infiltrates 
containing activated T cells (Aubock et al. 1986). Both Ly-2+ and L3T4+ T cells were shown to 
be capable of initiating epidermal cell necrosis, while predominately L3T4+ produced the 
lichenoid hyperplastic reaction common to acute GVHD (Piguet et al. 1987a). 
In 1988, studies documented that interferon-gamma (IFN-y) produced by activated 
donor T cells induced the de nova expression of class II on human epidermal keratinocytes 
(Dustin et al. 1988, Niederwieser et al. 1988). Subsequent immunohistochemical staining of 
human biopsies confirmed that IFN-y also upregulated the expression of intercellular adhesion 
molecule (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leucocyte 
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adhesion molecule-1 (ELAM-1) on epidermal keratinocytes (Dustin et al. 1988, Norton et al. 
1991, Norton and Sloane 1991). In addition to upregulating class II and adhesion molecule 
expression, IFN-y also upregulated tumor necrosis factor- alpha (TNF-u) production by local 
macrophages (Collart et al. 1986). Piguet et al. have demonstrated that mice undergoing acute 
GVHD did not develop cutaneous lesions and had significantly reduced mortality rates after 
being treated with recombinant murine anti-TNF-u (Piguet et al. 1987b). 
Intestinal GVHD. Diarrhea is a characteristic sign of acute GVHD in experimental 
animals and humans. In moderate GVHD, diarrhea is absent unless food is ingested, and 
anorexia becomes a prominent symptom. The most severe form of acute GVHD produces 
profuse watery diarrhea, protein loss, intestinal bleeding, mucosal denudation, edema of the 
intestinal wall, increasing pain and sepsis. Diarrheal fluid contains high concentrations of 
protein, cellular debris, and occult blood, resulting in a decrease of serum protein as diarrhea 
persists (Weisdorf et al. 1983). Acute GVHD most often affects the ileum and cecum, and viral 
infections may produce radiologic findings that mimic those produced by acute GVHD (Epstein 
et al. 1980, Snover et al. 1985, Jones et al. 1988). 
The clinical grading of intestinal GVHD is defined as: (1) Grade I - no gut 
involvement, (2) Grade II - diarrhea 500-1000 mUday and a mild decrease in clinical 
performance, (3) Grade Ill - diarrhea 1000-1500 mUday and a marked decrease in clinical 
performance, and (4) Grade IV - diarrhea exceeding 1500 mUday and an extreme decrease in 
clinical performance (Glucksberg 1974). In experimental animals early pathologic features 
include increased crypt cell mitotic activity, crypt lengthening and increased counts of 
intraepithelial lymphocytes as well as mucosa! mast cells (Wall, Rosenberg and Reilly 1971, 
Elson, Reilly and Rosenberg 1977). Late pathological features include villus atrophy, increased 
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crypt cell turnover, crypt cell necrosis and the loss of mucosal lymphoid cells (Elson, Reilly and 
Rosenberg 1977, Mowat and Ferguson 19S2, Snover et al. 19S5). 
Murine and rat studies have also determined that an upregulation of class II MHC 
antigens by enterocytes is another characteristic of acute GVHD (Mason, Dallman and Barclay 
19S1, Barclay and Mason 19S2, Guy-Grand and Vassalli 19S6). In control animals, class II 
MHC antigens were constitutively expressed at low levels on enterocytes although class II 
expression was absent on normal crypt cells. However, the development of acute GVHD 
upregulated class II expression on villus enterocytes and induced the de novo expression of 
class 11 on crypt cells (Barclay and Mason 19S2, Dilly and Sloane 19S7). 
Three (C3H x DBA/2) F1 murine models of acute GVHD were used to determine if 
T cell subsets induced enteropathy and upregulated class II MHC antigens throughout the 
development of acute intestinal GVHD (Guy-Grand and Vassalli 19S6). CD4+ T cells induced 
crypt hyperplasia and class II expression in irradiated recipients, while cos+ T cells induced 
histopathology in unirradiated adult and neonatal recipients. cos+ T cells infiltrated the mucosa 
more efficiently, while CD4+ T cells were markedly increased within intraepithelial lymphocyte 
populations and induced hyperplasia of mucosal mast cells. I mmunohistochemical studies of 
human rectal GVHD tissues following allogeneic BMT determined that the number of CDS+ T 
cells increased in both lamina propria as well as epithelium, and class II MHC antigen 
expression increased on epithelial cells in 7 out of S GVHD patients (Dilly and Sloane 19S7). In 
contrast to the increased number of CDS+ T cells within human rectal tissues, the number of 
CD4+ T cells remained the same. 
The induction of class II MHC antigens on villus enterocytes and crypt ~ells, 
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appeared to be determined by the presence of activated donor T cells and the production of 
IFN-y (Mowat 1989). Although the number of intraepithelial lymphocytes was increased in 
(CBA x BALB/c) F1 mice with acute GVHD, the administration of anti-IFN-y reduced crypt 
hyperplasia. These results suggested that IFN-y production was required to produce GVHD-
induced enteropathy. In addition to the corresponding effects of IFN-y in cutaneous and 
intestinal GVHD, TNF-a. has also been implicated as an effector mechanism of GVHD-induced 
enteropathy (Piguet et al. 1987b). None of the GVHD-induced (810 x CBA) F1 mice injected 
with recombinant murine anti-TNF-a. developed enteropathic lesions characteristic of acute 
GVHD. 
Adhesion molecules also appear to play important roles in the induction of acute 
GVHD enteropathy. Rectal biopsies from GVHD patients showed de novo ICAM-1 staining on 
the luminal surface of glandular epithelium (Norton et al. 1992). Although this staining was 
sometimes focal and variable in intensity it was present in all GVHD biopsies. In contrast, 
ELAM-1 staining was observed only on vascular endothelial cells within the most affected areas 
of the mucosa. Similar to ELAM-1, VCAM-1 staining was significantly positive on mucosal 
vascular endothelium and staining increased in proportion to the severity of GVHD. The de 
novo and upregulated expression of class II MHC antigens, the presence of IFN-y and TNF-a. 
induced histopathologies, the upregulation of adhesion molecules, and the extent of epithelial 
damage within cutaneous as well as intestinal organ compartments has suggested a common 
immunopathological pattern to acute GVHD. 
Hepatic GVHD. Signs of cutaneous and intestinal GVHD precede the onset of 
hepatic involvement. Although over 80% of all patients develop hepatic dysfunction following 
allogeneic BMT, only half of hepatic disease is a direct result of acute GVHD (Reviewed by 
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McDonald et al. 1987). Chemotherapy, viral infections, drug-induced liver injury, bacteremia, 
and hypotension are all significant sources of hepatic damage post-transplant. GVHD-induced 
hepatic histopathology includes cholectasis, scattered hepatocellular necrosis and jaundice. 
Serum levels of alkaline phosphatase and total bilirubin are increased 20 times over normal 
limits, although serum hepatocellular enzymes are less elevated. 
Clinical grading of hepatic GVHD is classified as: (1) Grade I - no liver 
involvement, (2) Grade II - bilirubin levels of 2 - 3 with a mild decrease in clinical performance, 
(3) Grade Ill - bilirubin levels of 3 - 15 with a marked decrease in clinical performance, and (4) 
Grade IV - bilirubin levels greater than 15 with an extreme decrease in clinical performance 
(Glucksberg 1974). Several studies have documented the progression of acute GVHD-induced 
liver histopathology. Clinical findings included mild nonspecific lobular hepatitis similar to viral 
or drug-induced hepatitis, and bile duct lesions were observed by light microscopy after 1-2 
weeks of GVHD (Snover et al. 1984, Shulman et al. 1988). Bile duct lesions affected small 
septal as well as interlobular bile ducts, and were characterized by segmental destruction of the 
duct wall, irregular nuclear enlargement, and cytoplasmic swelling. As GVHD progressed, 
cholestatic changes of the acinus became more obvious and endothelial cells were destroyed. 
lmmunohistochemical studies have also been conducted to define the role of T 
cells, class II MHC antigen expression, and the presence of adhesion molecules throughout 
hepatic GVHD. Immediately post transplant the numbers of TB+ and T4+ cells were markedly 
reduced in portal areas. However, the development of acute GVHD caused an increase in T8+ 
cells within portal tracts that did not exceed normal values, but were greater than post-
transplant values (Dilly and Sloane 1985). Additional immunohistochemical studies have 
determined that class II MHC antigen expression was expressed on epithelial cells in 4 out of 5 
patients (Norton, Al-Saffar, and Sloane 1992). Whereas no observable increase in ICAM-1, 
ELAM-1, or VCAM-1 staining occurred during hepatic GVHD. 
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Histopathologically, the 3 primary target organs of acute GVHD are characterized by 
the infiltration of lymphoid cells and epithelial destruction of cutaneous and mucosal barriers that 
facilitates the onset of lethal infections. Each of these organ systems demonstrates an increase 
in class II antigen expression and the numbers of COB+ or TB+ cytotoxic T cells. In addition, 
cutaneous and intestinal GVHD depict elevated levels of IFN-y and TNF- a as well as ICAM-1, 
VCAM-1 and ELAM-1 adhesion molecules. These common histopathologic and immunologic 
features of acute GVHD have established criteria for assessing the role of other potential 
GVHD-affected target organs. 
Interstitial Pneumonitis and Lymphocytic Bronchiolitis/bronchitis 
Interstitial pneumonitis. Interstitial pneumonitis (IP) has been recognized as a major 
cause of morbidity and mortality following BMT since the 1970's (Neiman et al. 1973, Meyers et 
al. 1975). A larger proportion of patients receiving allogeneic HLA-matched nonidentical bone 
marrow develop interstitial pneumonitis than the collective populations of autologous or 
syngeneic transplant patients (46% vs. 27%) (Crawford and Hackman 1993). Interstitial 
pneumonitis occurs with an incidence of 30-80% and results in a fatality rate of 50-60%. 
Although 60% of all interstitial pneumonitis occurs in conjunction with cytomegalovirus (CMV), 
30-45% can not be attributed to bacterial or viral infection and is considered to be idiopathic 
(Meyers, Flournoy and Thomas 1982). Overall, interstitial pneumonitis represents the second 
leading cause of death in 100-day survivors other than the recurrence of leukemia (Wingard, 
Santos and Sarai 1985). Clinically, the symptoms of interstitial pneumonitis include diffuse 
radiographic infiltrates, fever, dyspnea, non-productive cough, and hypoxemia (Meyers, Flournoy 
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and Thomas 1982, Wingard et al. 1988, Weiner et al. 1986). Histologically, IP is characterized 
as widespread perivascular mononuclear cell cuffing extending into the alveolar septa (Yousem 
et al. 1990). 
Clinical data have defined the main predictive factors of IP following allogeneic BMT 
to be: (1) prior cytomegalovirus infection of either the donor or recipient, (2) dose or dose-rate 
of lung irradiation, (3) sex-matching of the donor and recipient, (4) pre-transplant conditioning 
chemotherapy, (5) dose of bone marrow cells, (6) number of transfusions prior to transplant, (7) 
granulocyte transfusions post transplant, (8) immunosuppressive therapy, and (9) age of 
recipient (Appelbaum et al. 1982, Bartin et al. 1982, Meyers, Flournoy and Thomas 1982, 
Sloane et al. 1983, Weiner et al. 1986, Neiman et al. 1977, Weiner and Dicke 1987, Breuer et 
al. 1988). Although clinical and experimental studies have failed to determine if IP occurs as a 
direct result of acute GVHD, compiled data has suggested that three types of IP exist following 
allogeneic BMT: (1) radiation-induced IP, (2) CMV-induced IP, and (3) idiopathic IP. 
The effects of radiation on the lung have been documented since the early 1970's 
(Van Den Brenk 1971). The primary effects of radiation-induced lung injury occurs within the 
replicative mechanisms of pulmonary cells and reflects the proportion of cells irreparably 
damaged or killed resulting in depopulation. Cell damage and depopulation are responsible for 
the exudative, vascular and cicatricial changes known as radiation pneumonitis. The turnover 
rate of alveolar cells shows a direct correlation to the latent period that precedes the onset of 
radiation pneumonitis. Depopulation of alveolar cells reduces the production of alveolar 
surfactant and inhibits phagocytic capabilities. The loss of surfactant incurs osmotic collapse 
between the alveolar-capillary interface allowing the passage of blood transudates and 
hemorrhage into the alveolar lumen with excessive desquamation of damaged alveolar cells. 
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Consequently, instantaneous epithelial and endothelial damage occurs after irradiation that is 
not clinically apparent until after a "latent" period of 2 - 3 months (Rubin et al. 1980). In 
addition, the early decrease of type II lamellar bodies, increased cell turnover rates, pulmonary 
hemorrhage, and the presence of hyaline membrane disease often confuse the diagnosis of 
radiation pneumonitis with acute GVHD (Piguet et al. 1989, Wojno et al. 1994). 
There is also a direct relationship between the onset of interstitial pneumonitis and 
dose as well as dose-rate of irradiation used for pre-transplant conditioning (Keane et al. 1981, 
Barrett, Depledge and Powles 1983, Ringden et al. 1983). Both LA F1 and CBA murine models 
have shown that IP was produced from the synergistic effects of irradiation and acute GVHD 
(Lehnert, Rybka and Seemayer 1986, Down et al. 1992). These experimental studies have 
shown that radiation alone produced a "pneumonitis" which may occur concurrently with GVHD-
induced IP. Consequently, irradiation was not incorporated into the experimental protocols of 
this dissertation. 
Cytomegalovirus infection remains an serious risk factor to the long-term survival 
and success of allogeneic BMT patients. It is most often detected when acute GVHD is present 
in grades II - IV, and incurs a high rate of mortality because no effective treatment is available. 
Seropositivity of either donor or host is one of the primary risk factors in developing CMV-
induced IP (reviewed in Meyers et al. 1975, reviewed in Paulin et al. 1986). 
The vast clinical and experimental literature on CMV is outside the scope of this 
dissertation. However, several studies have shown that an interdependence exists between the 
onset of CMV, acute GVHD and interstitial pneumonitis. Grundy et al. injected adult 
nonirradiated (B10 x B10.A) F1 mice with murine CMV and a low dose of parental cells 
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(Grundy et al. 1985). The severity of acute GVHD was significantly increased despite the dose 
of parental lymphoid cells and IP was the prominent histopathological lesion observed within 
lung tissues. Clinical data have also shown that the simultaneous presence of acute GVHD and 
CMV significantly increased the incidence and mortality of IP (Neiman et al. 1973, 1976, 1977, 
Meyers, Flournoy and Thomas 1980, 1982, Miller et al. 1986, Cordonnier et al. 1986). 
Further research has shown that acute murine CMV augments the ability of 
parental spleen cells to induce GVHD (Via et al. 1988). Nonirradiated (B10 x B10.A) F1 mice 
were used to determine whether murine CMV infection produces a synergistic effect with GVHD 
through donor or host components. Donor mice inoculated with murine CMV 3 days prior to 
transplantation showed a reduced capacity to induce a GVHD-CMV associated IP, while murine 
CMV infection of the recipients 3 days prior to injection of parental cells exacerbated the 
development of IP. In addition, (B10 x B10.BR) F1 mice injected with 20 x 106 B10.BR spleen 
cells and murine CMV developed a severe diffuse pneumonitis that was not observed with 
either spleen cells or CMV alone (Shanley et al. 1987). More than 80% of the cells obtained by 
BAL and characterized using multiparameter flow cytometric analysis were determined to be 
donor Thy 1.2+ lymphocytes. In addition, 43% of BAL cells were L3T4+ and 38% were Lyt 2+. 
Consequently, an influx of donor T lymphocytes was observed during the development of IP as 
a result of GVHD and CMV. 
Lymphocytic bronchiolitis/bronchitis. Lymphocytic bronchitis (LB) may also be a 
consequence of acute GVHD (Beschorner et al. 1978). Lymphocytic bronchitis was 
characterized by the moderate to marked homogenous infiltration of small, darkly stained 
lymphocytes within the bronchial mucosa and submucosa. The basement membrane often 
appeared vacuolated, and the mucosa showed single-cell necrosis, a loss of ciliated cells, and a 
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decrease in the number of goblet cells. Hyperplastic regenerative mucosa with large basophilic 
irregular nuclei are often present within the upper respiratory tract, and squamous metaplasia 
may be evident (Beschorner et al. 1978, Yousem et al. 1990). Clinically, LB becomes evident 
as bronchopneumonia during acute GVHD of grades II -IV. Although LB is a serious 
complication of acute GVHD, it is not associated with CMV infection or a high rate of mortality. 
Pulmonary LB appears similar to the lymphocytic infiltration that occurs in the lamina propria 
causing mucosal necrosis during intestinal GVHD. 
The exacerbation of IP by acute GVHD and CMV infection, has confirmed the need 
to eliminate all traces of CMV from any protocol designed to assess pulmonary histopathology 
as a direct result of acute GVHD. Furthermore, clinical and experimental studies incorporating 
irradiation and/or CMV infection have failed to determine the immunopathology of acute GVHD-
induced "idiopathic" IP. Consequently, the characterization of acute GVHD-induced idiopathic 
IP and the development of a successful treatment to alleviate or control its onset remain critical 
to the future success of allogeneic BMT. 
CHAPTER Ill 
FLOW CYTOMETRIC ANALYSIS OF PULMONARY BRONCHOALVEOLAR LAVAGE AND 
COLLAGENASE-DIGESTED CELL SUSPENSIONS THROUGHOUT ACUTE LETHAL 
GRAFT-VS.-HOST DISEASE 
Introduction 
Graft-vs.-Host Disease (GVHD), a frequent and often lethal complication of 
allogeneic bone marrow transplantation (BMT), develops when donor T lymphocytes initiate an 
immune response to disparate host major and minor histocompatibility antigens (Korngold and 
Sprent 1990). However, depletion of T lymphocytes from the donor inoculum often abrogates 
engraftment and increases the rate of leukemic relapse (Weiden et al. 1981, Tutschka et al. 
1987, Korngold and Sprent 1990). The acute form of GVHD incurs a high incidence of mortality 
and diagnosis remains difficult due to the complicating effects of pre-transplant conditioning 
regimens. Therefore, defining the immunopathologic consequences of acute GVHD remains 
fundamental to the clinical management of allogeneic BMT patients. 
Pulmonary complications are a significant cause of mortality during acute GVHD. 
Many studies have implicated interstitial pneumonitis and lymphocytic bronchitis as the 
prevalent histopathologic elements of acute GVHD (Neiman et al. 1977, Beschorner et al. 1978, 
Sloane et al. 1983, Sullivan et al. 1986, Atkinson et al. 1991, Sloane and Norton 1993), but 
research has not determined a correlation between the onset of these histopathologies or their 
involvement throughout the development of a pulmonary syndrome that may be the direct result 
of acute GVHD. Previous studies have had difficulties discerning the initial cause of these 
complications due to the use of chemotherapeutic agents, irradiation, immunosuppressive drugs 
and overt infection. As a result, idiopathic interstitial pneumonitis has been implicated as a 
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direct consequence of acute GVHD but conclusive data has not been documented. 
Bronchoalveolar lavage (BAL) is an invasive procedure commonly used to 
access the cells and non-cellular components present on the epithelial surface of alveoli that 
are representative of ongoing inflammatory and immunological responses within the lower 
respiratory tract (Hunninghake et al. 1979, Reviewed by Reynolds 1987). Prior to the 
availability of monoclonal antibodies, differential counts of Wright-Giemsa-stained cytocentrifuge 
preparations provided the only means available to determine the phenotypes of cells within BAL 
samples. Today, BAL is routinely used in an attempt to diagnosis pulmonary infection, 
pathogenesis, allograft rejection and following bone marrow transplantation. Consequently, BAL 
and collagenase-digestion were used to determine if any variations in alveolar or parenchymal 
populations occurred throughout acute GVHD. Experimentally, BAL is used in conjunction with 
collagenase-digestion to produce mononuclear cell suspensions from pulmonary tissues. 
In the present study, BAL and collagenase-digestion were conducted according to 
standardized methods outlined for obtaining the optimal number of viable mononuclear cells 
from normal rat lung tissues (Holt 1979, Holt et al. 1985). BAL procedures were conducted 
prior to collagenase-digestion on adult nonirradiated (DA x LEW) F1 hybrid rats in the absence 
of chemotherapy, irradiation, immunosuppression and overt infection to detect phenotypic 
changes within alveolar and parenchymal compartments throughout acute lethal GVHD. BAL 
samples and collagenase-digests from control and GVHD-induced rats were incubated with a 
wide panel of mouse anti-rat monoclonal antibodies. 
Although previous studies quantified the results of immunoperoxidase staining by 
manually counting 300 - 500 labeled BAL and collagenase-digested cells (Holt and Schon-
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Hegrad 1987), the use of flow cytometric analysis (FACS) analysis has provided a quantitative 
method to measure phenotypic variations. Consequently, FACS analysis was used to 
determine if phenotypic variations occurred within BAL and collagenase-digests throughout 
acute GVHD. 
Materials and Methods 
Animals 
Lewis (LEW:RT1), DA (RT1a) and (DAxLEW) F1 hybrid rats were bred in the animal 
care facility at Loyola University Stritch School of Medicine. Acute, lethal GVHD was induced 
in 8 - 12 week old nonirradiated (DA x LEW) F1 rats by the intravenous injection of 1 x106 DA 
lymphoid (spleen and lymph node) cells/gram body weight as previously described (Clancy and 
Mauser 1981). All F1 animals injected with parental DA lymphoid cells developed classic signs 
of acute systemic GVHD by day 14, and 100% morbidity as well as mortality by day 21. 
To establish a control group, the lungs were excised on days 3 and 7 from 4 (2 
animals per time point) noninjected F1 rats, 4 GVHD-induced F1 rats, and 4 F1 animals 
intravenously injected with 1 x106 F1 lymphoid cells/gram body weight. All F1 animals were 
matched to litter and sex. Histological and quantitative data confirmed that there were no 
differences between noninjected and syngeneically-injected F1 animals compared on days 3 and 
7. In addition, the pulmonary histopathology present by day 7 in GVHD-induced F1 animals was 
absent in both noninjected and syngeneically-injected F 1 groups. Therefore, noninjected adult, 
nonirradiated F1 hybrid rats were used as controls throughout this study. 
Noninjected F 1 control and GVHD-induced animals were killed by ether overdose. 
GVHD animals were killed on days 3, 7, 10, 14, and 15 - 21 (5 animals per time point) 
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following injection. GVHD animals were matched to each other and corresponding controls by 
litter and sex when possible. All animal manipulations were approved by the Institutional Animal 
Care and Use Committee of Loyola University Chicago. 
Lung Preparation 
One control and one GVHD-induced F1 rat were killed for BAL and collagenase 
digestion per surgical session. The rats were placed ventral side up on a small metal rack tilted 
at a 45° angle within an 8 x 10 pyrex container. Suture (3 .0) was tied around each front limb at 
the distal joint and then to the metal rack. An incision was made horizontally along the distal 
edge of the diaphragm, then from the diaphragmatic border through the rib cage to the clavicle 
on each side, and horizontally from clavicle to clavicle. The frontal chest plate consisting of ribs 
and sternum was carefully removed so as not to disturb any thoracic organs. The descending 
aorta was severed above the diaphragm and a 50 cc syringe filled with PBS chilled to 4° C was 
attached to a 22 gauge butterfly needle placed within the right atrium. PBS was injected until 
the pulmonary vasculature was flushed and the lung tissue turned white. 
Bronchoalveolar Lavage 
After perfusion with PBS, the lungs with heart and trachea attached were removed 
from the rat by the distal end of the trachea. A 16 gauge needle was inserted approximately 2" 
into one end of a 3" length of 3 mm dialysis tubing. The other end of the tubing was cut on a 
45° angle. This tubing-needle apparatus provided an endotracheal device that was inserted 
within the trachea until the beveled end of the plastic tubing was just above the tracheal 
bifurcation. The endotracheal device was tied in place using 3.0 cuticle suture. The lungs, 
heart, and inserted endotracheal device were placed within a small clear plastic specimen bag 
with a ziploc edge. The ziploc edge was sealed around the protruding endotracheal device, and 
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the ziploc bag, containing the lungs, was placed within the circular depression of a poached egg 
tray and angled at 45° within the 8 x 10 pyrex container. The lung-filled ziploc bag was 
anchored to the plastic poached egg tray using hemostats. A 10 cc syringe was filled with 
Hanks Balanced Salt Solution (HBSS) warmed to 37° C containing 0.4% Lidocaine as 
previously described (Rabinovitch and Destefano 1976, Holt 1979). The syringe was attached 
to the endotracheal device and 10 cc of HBSS/Lidocaine was slowly injected until the lungs 
were fully expanded but without any surface leakage. The HBSS/Lidocaine was kept within the 
lung for 2 minute increments before the syringe was detached and the fluid allowed to drain by 
gravitational force into 50 cc conical tubes. The lungs were not manipulated by hand at any 
time. This process was repeated until 100 cc of HBSS/Lidocaine had been injected and the 
subsequent BAL fluid was collected. 
After BAL procedures were completed, the lungs were removed from the ziploc 
bags and the heart as well as bronchi were discarded. The BAL fluid was layered over 
Lymphocyte Separation Medium® and centrifuged for 30 minutes at 1800 RPM. The buffy coat 
was removed after centrifugation and washed 3 times in HBSS. 
Homogenization vs. Collagenase Digestion 
To ensure that collagenase-digestion provided optimal cell yields, experiments 
were conducted to determine the difference between homogenization and collagenase-digestion 
to obtain viable cell suspensions from spleens of F1 rats. Another preliminary experiment used 
various lots of secondary mouse anti-rat lgG Fab2 fragments conjugated to FITC on 
homogenized as well as collagenase-digested spleen, collagenase-digested lung, and BAL cell 
suspensions to assess the number of cells obtained as well as mean fluorescence intensity 
(MFI) (Table 1). An additional experiment was conducted using propidium iodide to remove 
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dead cells during FACS analysis (Table 2). Further preliminary studies labled collagenase-
digested spleen and homogenized spleen tissues with 5 monoclonal mouse anti-rat antibodies 
to demonstrate that collagenase-digestion was an optimal technique for obtaining parenchymal 
lung cell suspensions for FACS analysis (Tables 3 and 4). The data provided from these 
4 assays determined that collagenase-digestion in conjunction with propidium iodide assured an 
optimal number of viable cells as well as receptors, and appeared more effective than 
homogenization. 
Collagenase digestion 
The whole lung lobes were blotted dry, weighed and separated into .9 g increments 
that were sliced into 1 mm thick sections using a razor blade on dental wax. The sectioned 
lungs were placed into small glass mixing flasks and plastic coated stirring rods that had 
previously been cleaned with an ammonium hydroxide/ethanol solution for 24 hours prior to 
coating each flask and stirring rod with liquid Silicone (Sigma). The .9 grams of sliced lung 
tissue was placed into a siliconized flask with 32.43 mg of Type I Collagenase (150 U/ml), 43 µI 
of DNAse (50 U/ml), and 30 ml of PBS. The flasks were placed on stir plates within an 
incubator at 37° C for 90 minutes. After collagenase digestion was completed the mixture was 
layered over Lymphocyte Separation Medium ® and centrifuged at 1800 RPM for 30 minutes. 
The buffy coat was removed and washed 3 times in HBSS. The BAL and collagenase-digested 
cell suspensions were counted using Trypan Blue Exclusion, resuspended at a concentration of 
1 x 106 cells/ml chilled to 4° C. Each flask and stirring rod was cleaned overnight with an 
ammonium hydroxide/ethanol mixture and re-siliconized the next day. 
Antibody Labeling for Flow Cytometric Analysis 
All the antibodies used for labeling (Table 5) were diluted in PBS with 5% fetal calf 
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serum (FCS) to a final concentration of 1:100. One hundred microliters of BAL and 
collagenase-digested cell suspensions were added to individual wells of a microtiter plate. One 
hundred microliters of each antibody were added to corresponding rows of cell suspensions. 
One row received only 100 µI of PBS to serve as a control for nonspecific staining. The 
mononuclear cell/antibody suspensions were incubated for one hour at 4° C. After incubation, 
the plate was washed 3 times in PBS to prepare for addition of 2° antibody. Fab2 fragments of 
mouse anti-rat lgG conjugated to fluorescein (Cappel, Organo Technic Corp., Westchester, PA) 
noted as heavy and light chain specific was used as 2° antibody. One hundred micro liters of 2° 
antibody diluted in PBS to a final concentration of 1 :450 were added to each well and incubated 
for one hour at 4° C. After incubation, the plate was washed 3 times in PBS, and 100 µI 
propidium iodide diluted in PBS to a final concentration of 1 :100 were added to each well of the 
plate just prior to FACS analysis. 
Results 
Body Weight. Lung Weight. Lung Index 
Body weights, lung weights and lung indices were calculated for all control and 
GVHD animals (Tables 6 - 8). All animals were matched to sex and age when possible. Lung 
indices were calculated using the formula for spleen index (Simonsen 1962). The average lung 
index for day 7 (N = 3) was 1.47, for day 10 (N = 1) was 1.5, and for day 14 (N = 3) was 1.81. 
The percent difference between averaged day 7 and day 14 lung indices demonstrated an 
increase of 23.13 % which reflected a decrease in body weight. Lung weights averaged 2. 7 g 
regardless of sex or weight differences. 
Cell Yields From Parenchymal Collagenase Digests and BAL Fluid 
Although lung weights remained similar regardless of sex or weight differences, 
large fluctuations occurred within the cell yields obtained from day 7 collagenase digests. 
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Control male rats consistently produced more viable mononuclear cells from collagenase-
digested tissues as well as BAL samples on days 7 and 10 then corresponding female GVHD 
animals (Tables 9 - 12). However, cell yields obtained from the collagenase-digestion of female 
GVHD animals on day 14 were higher than control values regardless of sex (Table 13). BAL 
samples from the same animals did not show a consistent trend (Table 14). There may be a 
direct correlation between relative increases or decreases within BAL and collagenase-digested 
cell yields. An increased number of harvested BAL cells appear to accompany decreased 
parenchymal yields, while decreased BAL yields correspond to an increased number of 
parenchymal cells. 
FACS Analysis of Parenchymal and BAL Cells 
The initial testing of collagenase-digests and BAL cells was conducted using a final 
concentration of 2° antibody at 1 :150. However, this dilution provided an excess of non-specific 
staining and was retested to determine an optimal concentration of 1 :450. Although each 
monoclonal antibody labeled pulmonary BAL or collagenase-digested cell suspensions, at no 
time were the values obtained from FACS analysis consistent among control or GVHD animals 
(Tables 5, 15 - 19). 
Discussion 
FACS analysis of was used to assess the phenotypic variations within BAL and 
collagenase-digested cell suspensions taken from adult nonirradiated (DA x LEW) F1 hybrid rats 
throughout acute GVHD. Although the number of viable gated cells present within GVHD 
populations differed from those present in control cell suspensions, data were inconsistent for all 
animals and time points tested. However, there appeared to be a direct relationship between 
the number of cells obtained via BAL and collagenase-digestion. This correlation suggested 
that the process of BAL did not only recover mononuclear cells from the alveolar space, but 
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also harvested mononuclear cells from parenchymal tissues. Consequently, our results 
demonstrated that neither antibody-labeled BAL fluid nor collagenase-digested cell suspensions 
were capable of defining the onset, time course, anatomical location or severity of GVHD-
induced pulmonary histopathology. Therefore, the present study was extended to include 
histological and immunohistochemical analysis. 
Other reports comparing immunohistochemical analysis of transbronchial biopsies to 
FACS analysized BAL fluid support our conclusions. These studies indicate that BAL alone 
may be used to detect non-specific pathology or infection, although a combination of BAL and 
transbronchial biopsy provided more accurate results (Reviewed by Heurlin et al. 1989). In 
addition, BAL can not be relied upon to diagnose grades of allograft rejection or acute GVHD 
(Milburn et al. 1988, Leskinen et al. 1990, Reviewed by Shennib and Nguyen 1991 ). 
TABLE 1 
EFFICACY OF HOMOGENIZATION VS. COLLAGENASE 
DIGESTION AS DETERMINED BY USING DIFFERENT 
LOTS OF SECONDARY ANTIBODY 
Percent Mean 
Cell Suspensions Gated Fluorescence 
Cells Intensity 
Homogenized Spleen (0) 2.1 92.44 
Homogenized Spleen (M) 3.7 118.68 
Homogenized Spleen (N) 6.9 485.34 
Collagenized Spleen (N) 9.4 261.99 
Collagenized Lung (N) 12.6 214.73 
BAL (N) 7.0 412.36 
Old Secondary Antibody Staining with High Background (0) 
Secondary Antibody Obtained from Dr. Schneider (M) 
Replacement Secondary Antibody from Cappel (N) 
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TABLE 2 
EFFICACY OF HOMOGENIZATION VS. COLLAGENASE DIGESTION 
IN COMBINATION WITH PROPIDIUM IODIDE 
Percent Mean 
Cell Suspensions Gated Fluorescence 
Cells Intensity 
Homogenized Spleen (0) 12.6 835.46 
Homogenized Spleen (M) 13.6 828.52 
Homogenized Spleen (N) 14.0 823.37 
Collagenized Spleen (N) 15.1 781.63 
Collagenized Lung (N) 30.2 835.22 
BAL (N) 35.3 817.89 
Old Secondary Antibody Staining with High Background (0) 
Secondary Antibody Obtained from Dr. Schneider (M) 
Replacement Secondary Antibody from Cappel (N) 
Propidium 
Iodide Average 
for 5 Antibodies 
15.1 
15.2 
12.5 
17.0 
32.2 
36.6 
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TABLE 3 
EFFICACY OF HOMOGENIZATION VS. COLLAGENASE DIGESTION AS DETERMINED BY PRELIMINARY FLOW CYTOMETRIC ANALYSIS 
OX8 
Cell Suspensions 
% Gated 
Homogenized Spleen 26.2 
Collagenized Spleen 36.0 
Collgenized Lung 47.2 
BAL 12.4 
% Gated = Percent Gated Viable Cell 
MFI = Mean Fluorescence Intensity 
MFI 
198.48 
176.26 
159.02 
412.36 
OX12 OX19 
% Gated MFI % Gated 
37.4 232.11 62.3 
44.8 191.61 70.0 
30.4 164.46 59.5 
33.5 183.64 14.8 
W3/25 
MFI % Gated 
152.89 43.8 
127.84 53.3 
130.32 53.9 
314.29 13.9 
MFI 
120.91 
101.55 
114.03 
271.78 
ED1 
% Gated 
11.6 
53.9 
23.9 
18.9 
MFI 
220.67 
114.03 
157 .60 
294.29 
.,.. 
O> 
TABLE 4 
EFFICACY OF HOMOGENIZATION VS. COLLAGENASE DIGESTION 
AS DETERMINED BY PERCENT GATED DIFFERENCE AND 
MEAN FLUORESCENCE INTENSITY 
Antibody-Labeled Percent Gated Mean Fluorescence 
Spleen Cells Increase Intensity Decrease 
lgG only 27 46 
OX8 28 12 
OX12 17 18 
OX19 11 17 
W3/25 18 16 
ED1 21 52 
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TABLE 5 
FLOW CYTOMETRIC ANALYSIS OF CONTROL AND DAY 7 GVHD 
COLLAGENASE-DIGESTED CELL SUSPENSIONS 
Antibody 5/16/91 7/9/91 8/6/91 8/27/91 
c c I G c I G c I 
Dilution 1 : 150 Dilution 1 :450 
lgG 12.6 28.4 I 41.3 1.0 I 2.2 4.8 I 
Dilution 1:100 
MOPC10 5.9 1.3 5.2 
UPC21 5.1 1.5 5.0 
OX6 62.0 75.6 30.1 29.8 39.8 
OX8 47.2 60.0 66.0 51.2 23.2 39.6 
OX12 30.4 47.5 53.6 24.8 21.7 27.6 
OX19/52 59.5 29.3 73.9 54.0 38.9 40.9 
OX39 44.8 55.0 11.6 6.2 14.2 
OX41 36.3 
OX42 60.0 69.2 36.5 31.8 36.9 
W3/25 53.9 58.1 72.7 44.7 36.5 40.4 
ED1 23.9 38.4 65.6 37.2 24.3 33.0 
ED2 43.7 7.9 3.7 6.2 
C = Control Rats 
G = GVHD-lnduced Rats 
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G 
5.9 
7.3 
7.1 
44.1 
32.4 
34.0 
48.9 
21.1 
44.7 
46.9 
58.8 
27.2 
11.8 
TABLE 6 
BODY WEIGHT, LUNG WEIGHT AND LUNG INDEX OF CONTROL AND 
DAY 7 GVHD F1 HYBRID RATS 
7/9/91 8/6/91 8/27/91 
c G c G c G 
(Female) (Female) (Male) (Female) (Male) (Female) 
Body Weight (g) 238.7 233.6 368.8 224.5 378.0 203.0 
Lung Weight (g) 2.8 2.5 2.7 2.8 2.9 2.9 
Lung Index 0.92 1.64 1.84 
Date of Birth 2/19/91 4/9/91 6/2/91 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 7 
BODY WEIGHT, LUNG WEIGHT AND LUNG INDEX 
OF CONTROL AND DAY 10 GVHD 
F1 HYBRID RATS 
8/8/91 
c G 
(Male) (Female) 
Body Weight (g) 359.0 204.0 
Lung Weight (g) 2.9 2.4 
Lung Index 1.5 
Date of Birth 5/13/91 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 8 
BODY WEIGHT, LUNG WEIGHT AND LUNG INDEX OF CONTROL AND 
DAY 14 GVHD F1 HYBRID RATS 
7/16/91 8/13/91 9/3/91 
c G c G c G 
(Male) (Female) (Male) (Female) (Male) (Female) 
Body Weight (g) 235.0 188.0 361.0 193.5 360.0 163.7 
Lung Weight (g) 2.1 2.7 3.0 2.9 2.8 2.7 
Lung Index 1.55 1.88 2.00 
Date of Birth 2/19/91 5/13/91 6/2/91 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 9 
CELL YIELDS OF CONTROL AND DAY 7 GVHD COLLAGENASE-DIGESTED 
CELL SUSPENSIONS 
7/9/91 8/6/91 8/27/91 
c G c G c G 
(Female) (Female) (Male) (Female) (Male) (Female) 
Cell Yields (Millions) 4.0 8.0 27.6 16.5 17.8 16.0 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 10 
CELL YIELDS OF CONTROL AND DAY 7 GVHD BRONCHOALVEOLAR LAVAGE 
CELL SUSPENSIONS 
7/9/91 8/6/91 8/27/91 
c G c G c G 
(Female) (Female) (Male) (Female) (Male) (Female) 
Cell Yields (Millions) 2.0 2.8 3.6 2.8 11.7 2.2 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 11 
CELL YIELDS OF CONTROL AND DAY 10 GVHD 
COLLAGENASE-DIGESTED 
CELL SUSPENSIONS 
Cell Yields (Millions) 
C = Control Rats 
G = GVHD-lnduced Rats 
c 
(Male) 
11.6 
8/8/91 
G 
(Female) 
8.6 
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TABLE 12 
CELL YIELDS OF CONTROL AND DAY 10 GVHD 
BRONCHOALVEOLAR LAVAGE 
CELL SUSPENSIONS 
Cell Yields (Millions) 
C = Control Rats 
G = GVHD-lnduced Rats 
c 
(Male) 
6.8 
8/8/91 
G 
(Female) 
2.9 
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TABLE 13 
CELL YIELDS OF CONTROL AND DAY 14 GVHD COLLAGENASE-DIGESTED 
CELL SUSPENSIONS 
7/16/91 8/13/91 9/3/91 
c G c G c G 
(Female) (Female) (Male) (Female) (Male) (Female) 
Cell Yields (Millions) 7.5 28.2 30.8 51.1 45.3 50.4 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 14 
CELL YIELDS OF CONTROL AND DAY 14 GVHD BRONCHOALVEOLAR LAVAGE 
CELL SUSPENSIONS 
7/16/91 8/13/91 9/3/91 
c G c G c G 
(Female) (Female) (Male) (Female) (Male) (Female) 
Cell Yields (Millions) 2.4 2.7 9.2 5.1 1.7 5.4 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 15 
FLOW CYTOMETRIC ANALYSIS OF CONTROL AND DAY 7 GVHD 
BRONCHOALVEOLAR LAVAGE CELL SUSPENSIONS 
Antibody 5/16/91 7/9/91 8/6/91 8/27/91 
c c I G c I G c I G 
Dilution 1 : 150 Dilution 1 :450 
lgG 7.0 19.5 I 19.7 7.3 I 7.1 12.5 I 9.8 
Dilution 1 : 1 00 
MOPC10 6.4 7.7 12.1 
UPC21 6.7 11.9 11.3 
OX6 34.6 47.3 11.8 24.1 32.9 20.9 
OX8 12.4 25.2 31.1 13.1 26.8 18.3 16.8 
OX12 33.5 49.6 50.1 15.6 31.9 40.4 29.4 
OX19/52 14.8 28.5 38.6 17.9 20.3 25.5 5.0 
OX39 19.2 23.7 11.0 12.2 16.3 2.6 
OX41 63.9 67.0 
OX42 37.1 22.0 32.5 35.2 28.6 
W3/25 13.9 32.0 17 .1 19.3 29.6 8.0 
ED1 18.9 39.3 16.5 25.8 23.7 18.4 
ED2 6.9 9.5 12.1 8.6 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 16 
FLOW CYTOMETRIC ANALYSIS OF 
CONTROL AND DAY 10 GVHD 
COLLAGENASE-DIGESTED 
CELL SUSPENSIONS 
Antibody 8/9/91 
C G 
Dilution 1 :450 
lgG 15.3 9.7 
Dilution 1:100 
MOPC10 16.6 8.9 
UPC21 15.8 12.1 
OX6 46.6 50.8 
OX8 52.4 40.5 
OX12 34.7 41.8 
OX19/52 57.7 55.4 
OX39 28.3 29.4 
OX41 
OX42 53.4 58.3 
W3/25 58.0 63.0 
ED1 49.1 43.9 
ED2 20.2 17.8 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 17 
FLOW CYTOMETRIC ANALYSIS OF 
CONTROL AND DAY 10 GVHD 
BRONCHOALVEOLAR LAVAGE 
CELL SUSPENSIONS 
Antibody 8/9/91 
C G 
Dilution 1 :450 
lgG 21.5 7.4 
Dilution 1 : 100 
MOPC10 23.9 11.3 
UPC21 23.5 17.7 
OX6 45.3 26.1 
OX8 34.3 34.3 
OX12 51.2 28.4 
OX19/52 50.3 59.1 
OX39 30.7 20.7 
OX41 
OX42 54.2 30.1 
W3/25 49.4 48.7 
ED1 42.6 43.7 
ED2 23.1 14.0 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 18 
FLOW CYTOMETRIC ANALYSIS OF CONTROL AND DAY 14 GVHD 
COLLAGENASE-DIGESTED CELL SUSPENSIONS 
Antibody 7/16/91 8/13/91 9/4/91 
c I G c I G c I G 
Dilution 1 : 150 Dilution 1 :450 
lgG 18.9 I 23.5 3.7 I 2.4 12.7 I 6.6 
Dilution 1 : 1 00 
MOPC10 3.6 3.0 13.6 6.6 
UPC21 2.9 2.2 13.0 7.9 
OX6 39.3 86.0 30.3 58.8 45.3 77.1 
OX8 59.7 44.4 33.2 34.5 46.0 31.0 
OX12 35.3 36.8 26.2 23.9 39.7 24.0 
OX19/52 60.6 86.1 34.0 58.5 50.1 78.5 
OX39 49.5 9.9 9.7 23.9 29.0 
OX41 48.4 28.2 
OX42 45.9 25.4 30.1 46.2 32.8 
W3/25 53.9 84.7 30.9 58.9 47.6 80.7 
ED1 23.9 82.2 18.5 33.8 40.7 63.4 
ED2 55.7 5.9 9.5 
C = Control Rats 
G = GVHD-lnduced Rats 
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TABLE 19 
FLOW CYTOMETRIC ANALYSIS OF CONTROL AND DAY 14 GVHD 
BRONCHOALVEOLAR LAVAGE CELL SUSPENSIONS 
Antibody 7/16/91 8/13/91 9/4/91 
c I G c I G c I G 
Dilution 1 :150 Dilution 1 :450 
lgG 10.4 I 8.5 6.0 I 3.9 7.4 I 17.1 
Dilution 1 : 1 00 
MOPC10 6.5 4.5 7.0 17.2 
UPC21 5.8 3.7 7.5 16.2 
OX6 21.3 27.6 26.1 27.8 23.8 53.6 
OX8 14.5 12.4 11 .1 13.4 13.7 28.3 
OX12 21.4 45.5 26.3 30.3 28.5 38.2 
OX19/52 23.3 16.3 14.2 25.0 20.9 53.7 
OX39 9.6 16.6 6.2 9.1 24.4 
OX41 67.6 41.3 
OX42 29.1 39.6 26.3 32.6 31.7 46.8 
W3/25 20.4 16.0 13.7 32.0 22.9 57.8 
ED1 25.6 23.0 14.6 29.6 18.4 44.2 
ED2 6.0 7.9 
C = Control Rats 
G = GVHD-lnduced Rats 
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CHAPTER IV 
INTERSTITIAL PNEUMONITIS AND L YMPHOCYTIC BRONCHIOLITIS/BRONCHITIS AS A 
DIRECT RESULT OF ACUTE LETHAL GRAFT-VS.-HOST DISEASE DUPLICATE THE 
HISTOPATHOLOGY OF LUNG ALLOGRAFT REJECTION 
Abstract 
Pulmonary complications are often lethal components of acute Graft-vs.-Host Disease 
(GVHD). Although interstitial pneumonitis and lymphocytic bronchitis have been implicated as 
elements of acute GVHD, previous studies have not determined a correlation between the onset 
of these histopathologies or their contribution to a pulmonary syndrome that may occur as a 
direct result of acute GVHD. The present study used the adult, nonirradiated (DA x LEW) F1 
hybrid rat in the absence of chemotherapy, immunosuppressive drugs or overt infection to study 
these aspects of pulmonary pathology during acute GVHD. F1 animals were intravenously 
injected with 1 x 106 DA parental lymphoid cells/gram body weight which produced 100% 
morbidity and mortality by day 21. Neither syngeneically injected nor noninjected F1 control 
animals contained any observable or measurable histopathology. In addition, GVHD and 
control tissues did not contain bacterial, fungal, or CMV contamination as determined by specific 
tissue and immunohistochemical staining. GVHD animals were killed on days 3, 7, 10, 14, and 
15 - 21 following injection. Four micron, whole lobe tissue sections were stained with H&E, and 
histologic alterations within predetermined tissue sites were quantified using light-microscopic 
Image Analysis. Alveolar septal widths and perivascular infiltrate volume densities were 
increased significantly above controls by day 7, and reached 2.4 and 2.6 fold increases 
respectively by day 21. This data corroborated the development of an interstitial pneumonitis 
and lymphocytic bronchiolitis/bronchitis that duplicated the histopathology of lung allograft 
rejection. The discovery of pulmonary pathology corresponding to lung allograft rejection during 
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acute GVHD in the adult F1 rat implicates the lung as a potential target organ. 
Introduction 
Graft-vs-Host Disease (GVHD), a frequent consequence of allogeneic bone marrow 
transplantation (BMT), develops when donor T lymphocytes initiate an immune response to 
disparate host major and minor histocompatibility antigens (Korngold and Sprent 1990). 
However, the depletion of T lymphocytes from the donor inoculum often abrogates engraftment 
(Korngold and Sprent 1990). Therefore, defining the immunopathologic consequences of acute 
GVHD is fundamental to the clinical management of allogeneic BMT patients. 
The pulmonary complications of GVHD are consistently associated with an increase 
in morbidity and mortality. However, the initiation, progression and components of acute GVHD 
within the lung remain ill-defined and controversial. Many studies have implicated interstitial 
pneumonitis and lymphocytic bronchitis as prevalent elements during acute GVHD (Atkinson et 
al. 1991, Sloane and Norton 1993, Sloane et al. 1983, Beschorner et al. 1978, Neiman et al. 
1977, Sullivan et al. 1986, Stein-Streilein et al. 1981), but these studies have not determined a 
correlation between the onset of these histopathologies or their involvement throughout the 
development of a pulmonary syndrome that may be the direct result of acute GVHD. In 
contrast, several well-defined respiratory disorders are considered clinical manifestations of 
chronic GVHD (Stein-Streilein et al. 1981, Bradstock et al. 1984, Holland et al. 1988, Roca et al. 
1982, Ralph et al. 1982, Atkinson et al. 1984, Atkinson et al. 1989, Wyatt et al. 1984, Raschko 
et al. 1989). Some studies suggest that interstitial pneumonitis is characteristic of chronic 
GVHD (Sullivan et al. 1986, Piguet et al. 1989, Perreault et al. 1985, Wingard, Santos and Sarai 
1985). However, interstitial pneumonitis associated with chronic pulmonary disease is 
accompanied by fibrotic changes that are absent throughout the acute phase of GVHD. 
We have used the adult, nonirradiated (DA x LEW) F1 hybrid rat (Clancy and 
Mauser 1981) to investigate the possibilities that: (1) a pulmonary syndrome which duplicates 
the histopathology of lung allograft rejection develops as a direct result of acute GVHD, (2) 
interstitial pneumonitis and lymphocytic bronchiolitis/bronchitis are integral components of this 
syndrome, and (3) the lung is an important target organ of acute GVHD. This animal model, 
based on the injection of parental lymphoid cells into F 1 adults, consistently produced a 
systemic GVHD that paralleled the sequential organ involvement observed in allogeneic BMT 
patients. In addition, this model ruled out the influence of irradiation, chemotherapy, 
immunosuppression, and overt infection. Although irradiation has been incorporated into the 
majority of animal studies investigating GVHD, the present nonirradiated model omitted the 
primary lesions of epithelial and endothelial damage that accompany irradiation prior to 
experimentation (Rubin et al. 1980, Law, Ahier and Coultas 1986, Gross 1977, Travis 1980, 
Phillips 1966, Down 1986, Keane, Van Dyk and Rider 1981, Barrett, Depledge and Powles 
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1983, Kurohara and Casarett 1972, Van Den Brenk 1971), as well as the exacerbation of GVHD 
following irradiation (Down et al. 1992, Lehnert, Rybka and Seemayer 1986, Meyers, Flournoy 
and Thomas 1982). 
Materials and Methods 
Animals 
Lewis (LEW:RT1), DA (RT1a) and (DAxLEW) F1 hybrid rats were bred in the animal 
care facility at Loyola University Stritch School of Medicine. Acute, lethal GVHD was induced 
in 8 - 12 week old nonirradiated (DA x LEW) F 1 rats by the intravenous injection of 1 x 106 DA 
lymphoid (spleen and lymph node) cells/gram body weight as previously described (Clancy and 
Mauser 1981). All F1 animals injected with parental DA lymphoid cells developed classic signs 
of acute systemic GVHD by day 14, and 100% morbidity as well as mortality by day 21. 
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To establish a control group, the lungs were excised on days 3 and 7 from 4 (2 
animals per time point) noninjected F1 rats, 4 GVHD-induced F1 rats, and 4 F1 animals 
intravenously injected with 1 x 106 F 1 lymphoid cells/gram body weight. All F 1 animals were 
matched to litter and sex. Histological and quantitative data confirmed that there were no 
differences between noninjected and syngeneically-injected F1 animals compared on days 3 and 
7. In addition, the pulmonary histopathology present by day 7 in GVHD-induced F1 animals was 
absent in both noninjected and syngeneically-injected F1 groups. Therefore, noninjected adult, 
nonirradiated F1 hybrid rats were used as controls throughout this study. 
Noninjected F1 control and GVHD-induced animals were killed by ether overdose. 
GVHD animals were killed on days 3, 7, 10, 14, and 15 - 21 (6 animals per time point) 
following injection. GVHD animals were matched to each other and corresponding controls by 
litter and sex when po$sible. All animal manipulations were approved by the Institutional Animal 
Care and Use Committee of Loyola University Chicago. 
Histology 
The heart, lungs and trachea were removed intact and individual lobes were 
severed from the right mainstem bronchi. The left lung lobe was used for immunohistochemical 
analysis. Each right tung lobe was placed in 10% buffered formalin. Whole spleens and 
kidneys were dissected as controls for histological preparation and staining. 
All tissues were prepared for routine paraffin sectioning. Each lobe was sectioned 
at 4 µm along an anterior-posterior frontal plane at three differing tissue layers. A minimum of 
20 floating sections per tissue block were mounted on Superfrost Plus slides (Fisher, Pittsburgh, 
PA). Four micron, frontal anterior-posterior sections of spleens and kidneys were also 
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prepared. 
In addition to H&E staining, all tissues were tested with Brown-Brenn Gram and 
Grocotts Methenamine Silver stains to detect the presence of bacteria and fungi, respectively. 
lmmunohistochemical staining for cytomegalovirus was conducted using a combination of two 
monoclonal mouse anti-human antibodies, DDG9 and CCH2 (Dako, Carpenteria, CA) (Wirgart 
et al. 1990, Niedobitek et al. 1988). Tissues were randomly selected from animals killed on 
days 0 (control), as well as 7, 14, and 18 days following injection to rule out the presence of 
infection. All tissues were devoid of viral, fungal or bacterial contamination. 
Grading of Histopathology 
The grading system used throughout this study followed previously published 
guidelines used to classify the severity and progression of lung allograft rejection \( ousem et al. 
1990). 
Image Analysis 
Image analysis was accomplished using NIH Image installed on an Apple llcx 
computer interfaced to a Leitz (Optische Werke; Wetzlar, Germany) microscope using a Scion 
Image Capture Board (Scion Corp.; Frederick, MD) and a MOS Javelin Solid State video 
camera (Javelin Electronics; Torrance, CA). All images were digitized at a magnification of 
25X. Prior to each session, the microscope lamp was turned on for 30 minutes to stabilize the 
illumination source. Uniformity of the optical system was enhanced by automatically subtracting 
a blank field from a part of the slide not containing tissue with the illumination adjusted to an 
average pixel value of 127 on the Look-Up-Table (LUT). The optical density corresponding to 
specific tissue components was 148 - 238 on the LUT as determined by preliminary analyses of 
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random sections. 
A grid was designed to provide random, systematically reproducible tissue sites for 
quantification by image analysis. The grid pattern was superimposed on the center of each 
H&E-stained lung section. Points along the grid pattern were 80 µm apart and covered the 
entire tissue section without producing points outside the borders of the section. If a grid site 
did not contain measurable tissue it was not used. 
A total of 36 animals (6 animals per time point) was used in this study. Five 
random, systematically reproducible tissue sites were measured per tissue section, using the 
grid and selection criteria described above. To quantitate alveolar septal width, 6 equidistant 
length measurements perpendicular to the long axis were taken along the entire selected 
alveolar septae. To quantitate the volume density of perivascular infiltrates, circumferential and 
area measurements were obtained for the lumen, intima, and adventitial limiting plate of 
selected pulmonary vessels. The final volume density of the adventitial space was based on 
the optical density of perivascular infiltration as calculated by the LUT values described above. 
Mean values of the measurements obtained for alveolar septal width and 
perivascular infiltrate volume density were calculated for each tissue section. The final means 
from each animal were grouped according to the parameter measured and time point tested. 
Differences between the overall, cumulative means derived from each parameter and time point 
were tested for statistical significance using a one-way Analysis of Variance and Tukey post-hoc 
analysis (Spatz and Johnston 1984). 
Results 
Histology 
Neither syngeneically-injected F1 nor noninjected F1 control tissues contained any 
observable or measurable histopathology. Day 3 GVHD lung sections were also normal (data 
not shown). Therefore, all control and day 3 GVHD animals corresponded to Grade 0 lung 
allograft rejection criteria (Y ousem et al. 1990). The alveolar septae at both time points were 
normal in width and cellularity. Alveoli were free of hemorrhage, cellular debris and elevated 
numbers of macrophages. The perivascular adventitial space was delineated by an intact 
limiting plate (Yousem et al. 1992), and filled with loose connective tissue that contained 
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minimal cellularity. Bronchiolar smooth muscle and epithelium were normal, and were not 
surrounded or infiltrated by lymphocytes. Figure 1A represents a venule characteristic of control 
lung tissues. Figure 1 B represents alveolar septae characteristic of control lung tissues, and 
contains examples of alveolar septae chosen for quantification by image analysis. 
Day 7 GVHD tissue sections were characterized by the presence of infrequent 
perivascular mononuclear infiltrates that duplicated Grade 1 (Minimal acute rejection) (Yousem 
et al. 1990) allograft rejection criteria. Sites of perivascular infiltration were peripherally located 
throughout approximately 60% of each whole lung lobe tissue section, but were not obvious at 
low magnification. Both venules and arterioles were infiltrated with mononuclear cells, although 
the majority of affected vessels at day 7 were venules. Affected vascular adventitial spaces 
were infiltrated by small, round mononuclear cells layered 2-3 cells thick that appeared to 
migrate toward the adventitial limiting plate (Y ousem et al. 1992). By day 7, the majority of 
intra-luminal mononuclear cells demonstrated an apparent affinity for, and adherence to, the 
vascular endothelium. Figure 2A is representative of a day 7 vessel. Figure 2B depicts the 
presence of mononuclear cell adhesion and the variability of adventitial infiltration along a 
transverse section of pulmonary venule. In contrast to perivascular infiltration, peribronchiolar 
tissues remained normal at this time point. 
Day 10 GVHD tissue sections exhibited a transitional phase of histopathology. 
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Thirty percent of affected vessels within a tissue section demonstrated perivascular infiltration 
that duplicated Grade 1 criteria. However, 10% of affected vessels corresponded to Grade 2 
(Mild acute rejection) (Yousem et al. 1990) guidelines. The remaining 60% of affected vessels 
were in transition between Grades 1 and 2 as represented by Figure 3. The escalation of 
perivascular infiltration and alveolar septal thickening to Grade 2 began in peripheral vessels 
with a progressive escalation into the center of each lung lobe. Alveolar septae were 
significantly widened due to an increased cellularity and edema. In addition, by day 10, 20% of 
the terminal and respiratory bronchioles within a whole lung tissue section were surrounded by 
mononuclear infiltrates 2-3 cells thick (data not shown). 
The histopathology of day 14 GVHD tissue sections duplicated the parameters 
defined by Grade 2 (Mild acute rejection) criteria (Y ousem et al. 1990). Perivascular 
mononuclear infiltrates, that were easily recognizable at low magnification, surrounded more 
than 75% of all affected venules and arterioles. Adventitial spaces were densely infiltrated by 
mononuclear cells. Degenerative endothelialitis and decreased luminal area were also 
components of Grade 2 affected vessels. lntra-luminal lymphocytes demonstrated a strong 
affinity for the deteriorating vascular endothelium. Figure 4 is representative of Grade 2 
vessels. In addition, by day 14, lymphocytic infiltrates up to 5 cells thick were observed around 
60% of the bronchioles within a whole lobe tissue section, and small areas of peribronchiolar 
infiltrates had begun to invade the mucosa. 
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F 1 rats injected with parental cells developed a late-stage of acute GVHD between 
days 15 and 21. The late-stage included a subset of animals killed within an estimated 24 
hours of death that were classified as having end-stage disease. Imminent death was 
determined by the presence of severe physiologic parameters such as cachexia, diahrrea, skin 
lesions, deteriorated coat and kyphosis. 
Tissue sections from late-stage animals demonstrated a histopathology that 
corresponded to Grade 3 (Moderate acute rejection) (Yousem et al. 1990) allograft rejection 
guidelines. Extensive perivascular infiltrates were no longer contained by intact, limiting plates 
and had extended into the alveolar septae producing an interstitial pneumonitis as represented 
in Figure SA. Greater than 80% of affected vessels within a whole lobe section were classified 
as Grade 3. Late-stage pathology also included a distinct lymphocytic bronchiolitis that affected 
75% of the terminal and respiratory bronchioles within a whole lung tissue section. 
Peribronchiolar mononuclear cells had begun to invade the mucosa, submucosa and bronchiolar 
epithelium. Figure 58 is representative of the lymphocytic bronchiolitis present during late-stage 
GVHD. 
Tissue sections from end-stage GVHD animals exhibited extensive histopathology 
that corresponded to the criteria established for Grade 4 (Severe acute rejection) (Yousem et al 
1990) rejection guidelines. Grade 4 pulmonary disease affected 70% of each tissue section, 
while the remaining 30% exhibited histopathology that corresponded to Grades 1 through 3 of 
lung allograft rejection. The presence of Grade 4 histopathology was independent of individual 
lung lobes. Diffuse perivascular, interstitial and peribronchiolar infiltrates of mononuclear cells 
were characteristic of Grade 4 disease, and permeated whole lobe tissue sections. 
Endothelialitis was severe and all tissues were edematous. Parenchymal tissues were 
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hemorrhagic with an increased number of alveolar macrophages. Densely stained pyknotic 
nuclei were observed within lymphatic vessels, parenchymal tissues, and peribronchiolar 
infiltrates. By the end-stage of acute pulmonary GVHD, lymphocytic bronchiolitis had advanced 
to include the larger airways resulting in lymphocytic bronchitis. Figure 6 is representative of 
Grade 4 histopathology during end-stage acute GVHD. 
Interstitial Width and Volume Density Measurements 
Figures 7A and 7B represent data obtained from the quantification of variations in 
alveolar septal width and perivascular infiltrate volume density respectively. Alveolar septal 
width and perivascular infiltrate volume density measurements were significantly greater 
(p ~ 0.05) than control values by day 7. Both measured parameters reached a significance 
level of p ~ 0.001 compared to control values by day 10, and remained at that level of 
significance through day 21. Overall, alveolar septal width increased 2.4 times and perivascular 
infiltrate volume density increased 2.6 times as compared to control values by day 21. 
Similarities between the onset of statistical significance, the level of significance, and the overall 
trends of both graphs suggested that a similar mechanism(s) was present at the capillary and 
vessel level throughout acute GVHD. This mechanism(s) appeared to induce the quantifiable, 
concurrent increase in cellularity observed within alveolar septal and perivascular adventitial 
compartments. 
Discussion 
This study was designed to examine the pulmonary histopathology of acute lethal 
GVHD in the adult (DAxLEW) F1 hybrid rat without the influence of irradiation, chemotherapy, 
immunosuppressive drugs or overt infection. The results describe the initiation, progression and 
components of a sequential pulmonary pathology that occurred as a direct result of acute 
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GVHD, and duplicated the histopathology of lung allograft rejection (Yousem et al. 1990). 
A critical aspect of this study was the exclusion of irradiation prior to the induction 
of acute lethal GVHD. Most studies have incorporated irradiation into experimental GVHD 
protocols, or compiled data from irradiated BMT patients. However, both total-body irradiation 
and partial upper-body irradiation are known to cause immediate alveolar epithelial damage as 
well as capillary endothelial damage in the absence of disease (Gross 1977, Van Den Brenk 
1971). Irradiation also initiates the development of radiation pneumonitis, and exacerbates the 
pulmonary histopathology of GVHD (Down et al. 1992, Lehnert, Rybka and Seemayer 1986, 
Meyers, Flournoy and Thomas 1982). The early histopathology of irradiation damage is often 
overlooked during the examination of tissue by light or electron microscopy because initial 
alveolar epithelial and capillary endothelial changes are not widespread (Phillips 1966). In 
addition, radiation pneumonitis has been diagnosed routinely by pulmonary function assays that 
can not assess the cell damage or depopulation which initiate the latent period that precedes 
radiation pneumonitis (Van Den Brenk 1971 ). 
In contrast to previous murine (Piguet et al. 1989) and human (Atkinson et al. 1991) 
studies, the present nonirradiated model of acute lethal GVHD produced sequential pulmonary 
pathology between days 7 and 21 without similar epithelial or endothelial damage. Alveolar 
epithelium appeared normal throughout our study as suggested by the absence of hyaline 
membrane disease and a lack of mitotic figures within alveolar septae. 
Obvious capillary endothelial damage was also absent. Unlike a previous study 
(Piguet et al. 1989), we did not conduct electron microscopic studies to examine the presence 
of endothelial blebbing and basement membrane separation, but it is unlikely that the 
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nonirradiated capillary endothelium was damaged when more manifest signs of endothelial 
alterations, such as intra-alveolar hemorrhage and an increased number of intra-alveolar 
macrophages, were not observed. Ninety-eight percent of our tissue remained free from intra-
alveolar hemorrhage, high levels of intra-alveolar macrophages and debris throughout the 
course of acute GVHD. However, hemorrhage was widespread within alveolar septae during 
the late-stage of disease. Furthermore, alveolar capillaries were not filled with PMN's, alveolar 
septae did not contain eosinophils, and alveolar septal edema was not present until after day 
10. 
In the present nonirradiated model, alveolar septal and perivascular infiltrates began 
simultaneously but remained discrete until the late-stage of GVHD. Subsequently, dense 
perivascular infiltrates dispersed from adjacent adventitial limiting plates and coalesced with 
alveolar septal infiltrates to produce interstitial pneumonitis. In addition, peribronchiolar 
infiltrates developed while dense perivascular infiltrates were contained within intact adventitial 
limiting plates. 
We believe that the affinity/adherence of intra-vascular mononuclear cells to the 
vascular endothelium marks the onset of perivascular infiltration as a direct result of acute 
GVHD, and is critical to the eventual development of interstitial pneumonitis. We hypothesize 
that the affinity/adherence of mononuclear cells to the vascular endothelium is induced by the 
presence of activated intra-vascular host or donor cells. These activated cells may produce 
increased levels of cytokines which upgrade endothelial adhesion molecules such as ICAM-1. 
Cytokines such as TNF-a, IL-4 and IFN-y have been implicated in the upregulation of adhesion 
molecules (Thornhill et al. 1991, Huchet et al. 1993) and the development of GVHD (Piguet et 
al. 1989, Clancy, Goral and Kovacs 1990). Furthermore, the upregulation of adhesion 
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molecules, such as ICAM-1, coincide with the mononuclear cell infiltration of other GVHD 
affected organs (Dustin et al. 1988, Norton et al. 1991, Norton and Sloane 1991). In addition, 
the reduced flow rate of activated intra-vascular mononuclear cells within small peripheral 
pulmonary vessels may optimize the ability of initial cytokine levels to upregulate endothelial 
adhesion molecules. Higher levels of cytokines produced throughout the progression of acute 
GVHD may increase the density of endothelial adhesion molecules within successively larger 
vessels and subsequently recruit larger vessels to exhibit intra-vascular mononuclear cell 
affinity/adherence and infiltration. In our model, perivascular infiltration began around peripheral 
venules and arterioles. Larger vessels were not affected until later in the disease process. 
Therefore, larger vessels may have been affected earlier in a previous study (Piguet et al. 1989) 
due to the exacerbating effects of irradiation on GVHD (Down et al. 1992, Lehnert, Rybka and 
Seemayer 1986). 
Previous murine (Piguet et al. 1989) and human (Atkinson et al. 1991) 
investigations attempted to alleviate the pulmonary histopathology of acute, lethal GVHD using 
anti-cytokine administration and immunosuppressive therapy, respectively. Anti-TNF-a reduced 
only alveolar hemorrhage, while methylprednisolone and cyclosporine protocols reduced only 
peribronchial, perivascular and alveolar infiltrates. Neither method was able to abrogate 
irradiation-induced pathologies. These results reiterate our belief that the pulmonary 
consequences of GVHD can not accurately be assessed in an irradiated model. 
The present model of acute GVHD has previously been used to document cellular 
changes within other organs. A significant increase in T cells occurred within spleen and lymph 
nodes during the first 7 days after GVHD induction (Clancy and Mauser 1981). Subsequent to 
the increase, T cell populations decreased significantly from day 7 to day 21 (Clancy and 
Mauser 1981). Middle and later stages of this disease model also produced a significant 
infiltration of lymphoid cells into the periductal connective tissue of submandibular glands 
(Clancy, Klein and Weddle 1981) and periportal areas of the liver (Klein, Clancy and Stuart 
1982). Further studies are required to determine whether the infiltration of mononuclear cells 
observed within the lung, submandibular gland and liver represents specific donor anti-host 
interactions as a result of parental lymphoid administration. 
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The simultaneous development of pulmonary histopathologies due to irradiation and 
GVHD within acute GVHD studies incorporating irradiation, prompted us to compare our 
observations with those that occur during lung allograft rejection. The lung allograft rejection 
criteria established by Yousem et al. (Y ousem et al. 1990) are the most comprehensive 
rejection guidelines available. According to Yousem et al. (Yousem et al. 1990), acute rejection 
is characterized by the presence of perivascular mononuclear infiltration and lymphocytic 
bronchiolitis/bronchitis. Data obtained from using the present model of acute GVHD 
corresponded to this grading system so well that we used the guidelines of Yousem et al. 
(Y ousem et al. 1990) to assess our histologic results. The only apparent differences between 
our results and the allograft rejection criteria were a lack of eosinophils and fewer neutrophils 
within the mononuclear infiltrates of acute GVHD. These variations may be a result of 
comparing human to rat tissues, or may reflect the subtle immunological differences between 
lung allograft rejection and GVHD pathology. 
The detection of TNF-a within lung allografts (DeMeester et al. 1993) and GVHD 
lungs (Piguet et al. 1989, Clancy, Goral and Kovacs 1990) underscores the similarities between 
these transplant models. In a recent study, TNF antiserum attenuates the loss of alveolar 
architecture, alveolar hemorrhage, mononuclear and PMN infiltration, and intra-alveolar 
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proteinaceous exudates of lung allografts (DeMeester et al. 1993). However, the 
histopathologic equivalent to the pathogenesis present in our day 10 animals (Grades 1-2) 
remains. The inability of TNF antiserum to fully abrogate pulmonary pathology during lung 
allograft rejection and GVHD suggests that additional pathogenic mechanisms may be present 
in both transplant models. Furthermore, the strong correlation between the histopathology 
observed during lung allograft rejection and GVHD implies that similar mechanisms may be 
involved. 
The histological and quantitative evidence obtained from this study have shown that 
a pulmonary syndrome characterized by the sequential development of interstitial pneumonitis 
and lymphocytic bronchiolitis/bronchitis occurred as a direct result of acute GVHD. 
Furthermore, the histopathology produced throughout acute GVHD duplicated the pathogenesis 
of lung allograft rejection (Y ousem et al. 1990). These findings strongly suggest that the lung is 
a target organ of acute lethal GVHD. Further studies will be necessary to elucidate the cellular 
components and mechanism(s) of pulmonary pathology throughout acute GVHD, and determine 
the reason why acute GVHD induces significant morphologic correlations to allograft rejection. 
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FIGURE 1. Photomicrographs representative of Control (Grade 0) lung tissue. 
(A) Adventitial space (a) and adventitial limiting plate (b) of a pulmonary venule. (B) Lung 
parenchyma containing alveolar septae suitable for quantification by Image Analysis (a). (H&E); 
Horizontal bars indicate 50 µm scale. 
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FIGURE 2. Photomicrographs representative of Day 7 GVHD (Grade 1) lung tissue. 
(A) Venular adventitial space with early perivascular infiltrate (a), intact limiting plate (b), and 
intraluminal mononuclear cell adherence (c). (B) Transverse section of a venule with 
perivascular infiltrate (a) and intraluminal mononuclear cell adherence (b). (H&E); Horizontal 
bars indicate 50 µm scale. 
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FIGURE 3. Photomicrograph representative of Day 10 GVHD (Grades 1-2) lung 
tissue. Increased perivascular infiltrate (a), intact limiting plate (b), and alveolar septa suitable 
for quantification by Image Analysis (c). (H&E); Horizontal bar indicates 50 µm scale. 
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FIGURE 4. Photomicrograph representative of Day 14 GVHD (Grade 2) lung tissue. 
Perivascular infiltrate (a), degenerative endothelialitis (b), decreased vascular lumen (c), and 
intact limiting plate (d). (H&E); Horizontal bar indicates 50 µm scale. 
85 
FIGURE 5. Photomicrographs representative of Late-stage GVHD (Grade 3) lung 
tissue. (A) Perivascular infiltrates extending into adjacent alveolar septae producing interstitial 
pneumonitis (a). (B) Mucosal (a), submucosal (b) and epithelial infiltration of peribronchiolar 
tissue by mononuclear cells producing a lymphocytic bronchiolitis (c). (H&E); Horizontal bars 
indicate 50 µm scale. 
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FIGURE 6. Photomicrograph representative of End-stage GVHD (Grade 4) lung 
tissue. Prominent interstitial pneumonitis (a). (H&E); Horizontal bar indicates 50 µm scale. 
88 
89 
90 
FIGURE 7. Alveolar septa! width and perivascular infiltrate volume density in 
noninjected (DA x LEW) F1 controls (day 0), and DA/F1 GVHD-induced, nonirradiated adult rats 
3, 7, 10, 14, and 15-21 days following injection. Data were obtained using quantitative Image 
Analysis. Error bars represent means ± SEM. Statistical analyses were conducted using a one-
way ANOVA and Tukey post-hoc testing. (•) = p::;0.05 and (••) = p::;0.001 as compared to 
control values. (A) N = 6 animals per time point and 750 alveolar septa! width measurements 
per animal. (8) N = 6 animals per time point and 500 perivascular infiltrate volume density 
measurements per animal. 
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CHAPTER V 
PHENOTYPIC ANALYSIS OF PULMONARY PERIVASCULAR MONONUCLEAR INFILTRATES 
THAT OCCUR AS A DIRECT RESULT OF ACUTE LETHAL GRAFT-VS.-HOST DISEASE 
DESCRIBES THE ONSET OF INTERSTITIAL PNEUMONITIS 
Abstract 
We recently determined that the sequential development of interstitial pneumonitis 
and lymphocytic bronchiolitis/bronchitis occurs as a direct result of acute lethal GVHD. 
Interstitial pneumonitis develops prior to lymphocytic bronchiolitis/bronchitis primarily from the 
dissemination of perivascular mononuclear infiltrates. We have used the adult, nonirradiated 
(DA x LEW) F1 hybrid rat in the absence of chemotherapy, immunosuppression, or overt 
infection to determine the phenotype of infiltrating perivascular mononuclear cells throughout 
acute lethal GVHD. F 1 animals were intravenously injected with 1 x 106 DA parental lymphoid 
cells/g body weight which produced 100% morbidity and mortality by day 21. GVHD animals 
were killed on days 3, 7, 10, 14, and 15 - 21 following injection. Whole left lungs were frozen, 
serially sectioned (4µm) and incubated with a panel of mouse anti-rat monoclonal antibodies. 
Labeled antibody density was determined by computerized Image analysis. A biphasic pattern 
of infiltration was observed first for ED1+, oxa+ and W3/25+ cells then OX41+, W3/13+ and 
OX19/52+ populations. OX6 was expressed in control tissues and all time points. OX12+, 
OX39+ and MOM/3F12/F2+ cells were not quantifiable. These class W, T-cell and macrophage 
populations initiated interstitial pneumonitis and indirectly pointed to an activated T-cell, 
cytokine-induced upregulation of adhesion molecules that may facilitate transportation of CMV. 
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Introduction 
Graft-vs.-Host Disease (GVHD), a frequent and often lethal complication of 
allogeneic bone marrow transplantation (BMn, develops when donor T lymphocytes initiate an 
immune response to disparate host major and minor histocompatibility antigens (Korngold and 
Sprent 1990). However, depletion of T lymphocytes from the donor inoculum often abrogates 
engraftment and increases the rate of leukemic relapse (Korngold and Sprent 1990, Tutschka et 
al. 1987, Weiden et al. 1981). The acute form of GVHD incurs a high incidence of mortality and 
diagnosis remains difficult due to the complicating effects of pre-transplant conditioning 
regimens. Therefore, defining the immunopathologic consequences of acute GVHD remains 
fundamental to the clinical management of allogeneic BMT patients. 
Pulmonary complications are a significant cause of mortality during acute GVHD. 
Many studies have implicated interstitial pneumonitis and lymphocytic bronchitis as the 
prevalent histopathologic elements of acute GVHD (Atkinson et al. 1991, Sloane and Norton 
1993, Sloane et al. 1983, Beschorner et al. 1978, Neiman et al. 1977, Sullivan et al. 1986). 
However, these studies have not determined a correlation between the onset of interstitial 
pneumonitis and lymphocytic brochiolitis/bronchitis or the development of GVHD-induced 
pulmonary symptoms. In a recent study, we determined that a pulmonary syndrome 
characterized by the sequential development of interstitial pneumonitis and lymphocytic 
bronchiolitis/bronchitis occurs as a direct result of acute lethal GVHD (Workman and Clancy 
1994). In the absence of irradiation, chemotherapeutic agents, immunosuppressive drugs or 
overt infection, we demonstrated that acute GVHD-induced interstitial pneumonitis develops 
prior to lymphocytic bronchiolitis/bronchitis through the coalescence of perivascular and alveolar 
septal mononuclear cell infiltrates. In addition, the histopathology produced through the 
development of interstitial pneumonitis and lymphocytic bronchiolitis/bronchitis duplicates the 
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pathogenesis of lung allograft rejection. Consequently, our previous study established that the 
lung is an important target organ of acute lethal GVHD. 
Perivascular mononuclear cell infiltration appears to be the most prominent, 
quantifiable and reliable parameter of developing acute pulmonary GVHD (Workman and Clancy 
1994). Consequently, in the present study we have used the adult, nonirradiated (DA x LEW) 
F 1 hybrid rat and a comprehensive panel of mouse anti-rat monoclonal antibodies to: 
(1) determine the phenotype of perivascular mononuclear cell infiltrates throughout the course of 
acute GVHD, (2) assess the "position" of labeled mononuclear cells within the perivascular 
adventitial space relative to the adventitial limiting plate (Workman and Clancy 1994, Yousem et 
al. 1992), and (3) quantify the density of antibody-labeled perivascular mononuclear cell 
populations throughout the course of acute lethal GVHD. 
Materials and Methods 
Animals 
Lewis (LEW:RT1 1), DA (RT1a) and (DAxLEW) F1 hybrid rats were bred in the animal 
care facility at Loyola University, Stritch School of Medicine. Acute, lethal GVHD was induced 
in 8 - 12 week old nonirradiated (DAxLEW) F 1 rats by the intravenous injection of 1 x 106 DA 
lymphoid (spleen and lymph node) cells/gram body weight as previously described (Clancy and 
Mauser 1981). All F1 animals injected with parental DA lymphoid cells developed classic signs 
of acute systemic GVHD by day 14, and 100% morbidity as well as mortality by day 21. 
To establish a control group, the lungs were excised on days 3 and 7 from 4 
(2 animals per time point) noninjected F1 rats, 4 GVHD-induced F1 rats, and 4 F1 animals 
intravenously injected with 1 x 106 F 1 lymphoid cells/gram body weight. All F 1 animals were 
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matched to litter and sex. Histological and quantitative data confirmed that there were no 
differences between noninjected and syngeneically-injected F 1 animals compared on days 3 and 
7. In addition, the pulmonary histopathology present by day 7 in GVHD-induced F1 animals was 
absent in both noninjected and syngeneically-injected F1 groups. Therefore, noninjected adult, 
nonirradiated F1 hybrid rats were used as controls throughout this study. 
Noninjected F1 control and GVHD-induced animals were killed by ether overdose. 
GVHD animals were killed on days 3, 7, 10, 14, and 15 - 21 (5 animals per time point) 
following injection. GVHD animals were matched to each other and corresponding controls by 
litter and sex when possible. All animal manipulations were approved by the Institutional Animal 
Care and Use Committee of Loyola University Chicago. 
I mmunohistochemistrv 
The heart, lungs and trachea were removed intact, and all four right lung lobes were 
prepared for histological analysis as previously described (Workman and Clancy 1994). A 
1 mm segment of distal left lung was removed to allow for drainage of fixation materials. The 
left lung was intra-tracheally injected with 50 cc of 4% paraformaldehyde (PFA) chilled to 4° C 
until the lung lobe was completely distended for at least 30 seconds. After PFA injection, 20 cc 
of Ames OCT Compound (Miles Lab, Inc., Elkhart, Ind.) was intra-tracheally injected until the 
OCT flowed from the distal lobe incision. The left lung was dissected from the left mainstem 
bronchi and divided in half horizontally. Each lung half was placed in 4% PFA for 2 - 4 hours at 
4° C. After PFA submersion, each lung half was placed in 20% sucrose at 4° C for 12 - 48 
hours. Following sucrose immersion, all tissues were submersed in OCT compound, frozen in 
liquid nitrogen and stored at -70° C. Whole spleens (positive control) and kidneys (negative 
control) were also dissected, fixed and frozen according to the above immunohistochemical 
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protocol. 
Serial sections (4 µm) were cut from each lung, spleen and kidney tissue specimen 
along an anterior-posterior frontal plane on a Leitz 1720 Digital Cryostat at -20° C. Sections 
were arranged two per slide providing serial sections on successive slides that enabled 
immunostaining of separate antibodies on serial sections. Each slide contained two whole lobe 
lung, kidney or spleen serial sections from differing tissue layers. The slides were mounted on 
Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA), air-dried and stored at -20° C. 
lmmunohistochemical analysis was conducted using an avidin-biotin staining 
method. All tissue sections were initially blocked with 10% fetal calf serum (FCS) in 0.1 M Tris 
buffer (pH 7.2) for 30 minutes at 22°. Each primary mouse anti-rat monoclonal antibody 
(Bioproducts for Science, Inc., Serotec, Indianapolis, In) (Table 20) was individually titrated on 
sections of lung, spleen (positive control) and kidney (negative control) to achieve optimal 
dilutions in 10% FCS in Tris buffer and incubated for 1 hour at 22°. Sections were 
subsequently washed in Tris buffer with 1 % Triton-X (2 x 10 min) followed by Tris buffer without 
Triton-X (2 x 10 min). The secondary antibody, biotinylated sheep anti-mouse lg (1 :200) 
(Amersham, Arlington Hts, IL), was diluted in 10% FCS in Tris buffer and incubated 1 hour at 
22°. Endogenous peroxidase was blocked by treatment with hydrogen peroxide (0.3%) in 100% 
methanol (30 min). Standard peroxidase-conjugated streptavidin (1 :200) (Dako, Carpinteria, 
CA) and DAB (Sigma Chemical Co, St. Louis, Mo) protocols were used to visualize the 
chromagen. All DAB-stained tissues were intensified with Osmium Tetroxide (Electron 
Microscopy Sciences, Fort Washington, PA), dehydrated, counter-stained with hematoxylin, and 
mounted in Permount. Controls consisted of adjacent sections incubated either with normal 
mouse serum (matched for protein concentrations) or isotype-matched antibodies (LJPC10, lgG2a 
97 
and MOPC 21, lgG1) (Sigma) in place of the respective antibodies. Each of these controls was 
negative. 
In addition to immunohistochemical staining, all tissues were tested with Brown-
Brenn Gram and Grocotts Methenamine Silver stains to detect the presence of bacteria and 
fungi, respectively. CMV inclusion bodies were absent within all lung tissues tested according 
to light microscopic examination. lmmunohistochemical staining for cytomegalovirus (CMV) was 
conducted using a combination of two monoclonal mouse anti-human antibodies, DDG9 as well 
as CCH2 (Dako, Carpenteria, CA) (Wirgart et al. 1990, Niedobitek et al. 1988) to confirm the 
absence of CMV. Mouse anti-human antibodies were used because mouse anti-rat 
mononclonal antibodies to CMV were not available. Tissues were randomly selected from 
animals killed on days 0 (control), as well as 7, 14, and 18 days following injection to rule out 
the presence of infection. All tissues were devoid of viral, fungal or bacterial contamination. 
Image Analysis 
Image analysis was accomplished using NIH Image installed on an Apple Macintosh 
llcx computer interfaced to a Leitz (Optische Werke; Wetzlar, Germany) microscope using a 
Scion Image Capture Board (Scion Corp.; Frederick, MD) and a MOS Javelin Solid State video 
camera (Javelin Electronics; Torrance, CA). All images were digitized at a magnification of 
40X. Prior to each session, the microscope lamp was turned on for 30 minutes to stabilize the 
illumination source. Uniformity of the optical system was enhanced by automatically subtracting 
a blank field from a part of the slide not containing tissue with the illumination adjusted to an 
average pixel value of 127 on the Look-Up Table (LUT). The optical density corresponding to 
specific tissue components was calculated on the LUT as determined by preliminary analyses of 
random sections (Table 20). 
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A grid was designed to provide random, systematically reproducible tissue sites for 
quantification by Image Analysis. The grid pattern was superimposed on the center of each 
immunohistochemically-stained lung section. Points along the grid pattern were 80 µm apart 
and covered the entire tissue section without producing points outside the borders of the 
section. If a grid site did not contain measurable tissue it was not used. 
Thirty animals (5 animals per time point) were used in this study. Ten random, 
systematically reproducible tissue sites were measured per tissue section, using the grid and 
selection criteria described above. To quantitate the density of antibody-labeled mononuclear 
cells (volume density) within perivascular infiltrates, circumferential and area measurements 
were obtained for the lumen and adventitial limiting plate of selected pulmonary vessels. The 
final volume density of the adventitial space was based on the optical density of perivascular 
infiltration as calculated by the LUT values described above. 
Statistics 
Mean values of the measurements obtained for perivascular infiltrate volume density 
were calculated for each tissue section. The final means from each animal were grouped 
according to the time point tested. Differences between the overall, cumulative means derived 
from each time point were tested for statistical significance. Each antibody-labeled cell 
population was assessed for statistical significance by comparing the volume density 
measurements obtained from the first time point that yielded quantifiable results to subsequent 
time points. One-way Analysis of Variance and Tukey post-hoc analysis (Spatz and Johnson 
1984) were used to provide continuity with standards employed to assess the histopathology of 
acute pulmonary GVHD as previously described (Workman and Clancy 1994). 
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Results 
Volume Density 
Of the ten monoclonal antibodies selected for immunohistochemical analysis, seven 
provided staining within whole lobe lung tissues (Table 20). However, OX12 (Mason et al. 
1983), OX39 (Paterson et al. 1987) and MOM/3F12/F2 (Billett, Gunn and Mayer 1984) 
antibodies did not exhibit staining within the perivascular adventitial space at any time point 
tested. Peak volume density measurements for OX6-, ED1-, OX8-, W3/13-, W3/25- and 
OX19/52-labeled mononuclear cells were obtained on day 14. Only volume density 
measurements of OX41-labeled mononuclear cells were maximal between days 15 - 21. The 
slight drop in volume density measurements within OX6-, OX8- and W3/25-labeled mononuclear 
cell populations between days 15-21 resulted from dissolution of the perivascular adventitial 
limiting plate and a subsequent increase within the total area measured. Decreased volume 
density measurements from ED1-, W3/13- and OX 19/52-labeled mononuclear cell populations 
resulted from both a decrease in labeled perivascular cells and dissolution of the perivascular 
adventitial limiting plate. 
Figure 8 A is representative of OX6 (McMaster and Williams 1979, Mason, Dallman 
and Barclay 1981) staining within the perivascular adventitial spaces of control tissues. One to 
three OX6-labeled mononuclear cells were found consistently within the narrow perivascular 
space. The small perivascular volumes combined with the presence of OX6-labeled cells 
produced exaggerated volume density values for day 0 (control) (Figure 10). Day 3 volume 
density measurements were substantially reduced from control values and became more 
representative of histological data as previously described (Workman and Clancy 1994). Day 3 
volume density measurements were reduced because the number of OX6-labeled mononuclear 
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cells within day 3 perivascular spaces remained consistent with the number of labeled cells in 
the perivascular spaces of control tissues, yet the perivascular spaces in day 3 tissues were 
increased. As a consequence of this finding, OX6 data from days 7, 10, 14 and 15 - 21 were 
statistically compared to day 3 volume density measurements. Day 10 OX6 volume density 
measurements increased 2.8 times (Ps;,0.05) as compared to day 3 values. Days 14 and 15-21 
increased 3.7 - 3.6 times respectively (Ps;,0.01) as compared to day 3 measurements (Figure 
10). 
Figure 8 B is representative of OX6 labeling obtained in the advanced stages of day 
14 perivascular mononuclear cell infiltration. During initial perivascular infiltration on day 7, 
OX6-labeled mononuclear cells were adjacent to the perivascular limiting plate (data not 
shown). By day 14, OX6-labeled cells appeared to be uniformly distributed within the 
perivascular space (Figure 8 B). 
Figure 8 C is representative of ED1 (Dijkstra et al. 1985) labeling in the early stages 
of day 14 perivascular mononuclear cell infiltration. Day 14 volume density measurements were 
increased 2.4 times (P s;, 0.01) as compared to day 7 values (Figure 11 A). Volume density 
measurements obtained between days 15 - 21 returned to the same overall value calculated for 
ED1-labeling on day 10. During early infiltration of the perivascular space on day 7, ED1-
labeled cells were positioned midway between the endothelium and perivascular limiting plate 
(data not shown). By day 14, ED1-labeled mononuclear cells were observed dispersed 
throughout the perivascular space (Figure 8 C). 
Figure 8 D is representative of OX41 (Robinson, White and Mason 1986) labeling in 
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the early stages of perivascular mononuclear cell infiltration between days 15 - 21. Although 
volume density measurements from days 15 - 21 increased 1. 7 times over day 14 values, the 
increase was not calculated to be significant (Figure 11 B). However, OX41 was the only 
monoclonal antibody used in the present study that showed increased labeling between days 
15 - 21. During early infiltration of the perivascular space on day 14, OX41-labeled 
mononuclear cells were adjacent to the adventitial limiting plate (data not shown). Between 
days 15 - 21, OX41-labeled mononuclear cells were dispersed throughout the adventitial space 
(Figure 8 D). 
Figure 9 A is representative of OX8 (Mason et al. 1983, Barclay 1981, Dallman, 
Mason and Webb 1982) staining in the early stages of day 14 perivascular mononuclear cell 
infiltration. Although day 14 volume density measurements increased 1.8 times over day 7 
values, the increase was not calculated to be significant (Figure 12 A). During early infiltration 
of the perivascular space on day 7, OX8-labeled mononuclear cells were located within the 
perivascular adventitial space midway between the endothelium and adventitial limiting plate 
(data not shown). By days 15 - 21, OX8 labeled mononuclear cells were dispersed throughout 
the perivascular space (Figure 9 A). 
Figure 9 B is representative of W3/13 (Brown et al. 1981, Dyer and Hunt 1981) 
staining within the perivascular mononuclear cell infiltration characteristic of day 14. Although 
day 14 volume density measurements increased 2.0 times over values obtained between days 
15 - 21, the increase was not calculated to be significant (Figure 12 B). During initial infiltration 
on day 14, W3/13-labeled mononuclear cells were positioned midway between the endothelium 
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and adventitial limiting plate. Although volume density measurements from days 15 - 21 were 
decreased, W3/13-labeled cells were dispersed throughout the perivascular space (Figure 9 B). 
Figure 9 C is representative of W3/25 (Mason et al. 1983, Barclay 1981, Brideau et 
al. 1980) staining within the perivascular mononuclear cell infiltration characteristic of day 14. 
Days 14 and 15 - 21 were increased 3.8 - 3.4 times respectively (P ~ 0.01) over day 7 volume 
density measurements (Figure 13 A). During the early infiltration of mononuclear cells on day 
7, W3/25-labeled cells were observed midway between the endothelium and adventitial limiting 
plate (data not shown). By day 14 W3/25-labeled cells were dispersed throughout the 
perivascular space (Figure 9 C). 
OX19/52 
OX52 (Robinson, Puklavec and Mason 1986) has been shown to augment OX19 
(Dallman, Thomas and Green 1984) staining on cryostat sections (Robinson, Puklavec and 
Mason 1986). Preliminary data for the present study also determined that neither OX19 nor 
OX52 alone exhibited the intensity of immunohistochemical staining that was obtained when 
both antibodies were combined. Consequently, an equal mixture of OX19 and OX52 was used 
to indicate pan T-cell phenotyping throughout this study. 
Figure 9 D is representative of OX 19/52 staining in the early stages of day 14 
perivascular mononuclear cell infiltration. Although day 14 volume density measurements 
increased 2.2 times over values obtained between days 15 - 21, the increase was not 
calculated to be significant (Figure 13 B). During early infiltration of mononuclear cells on day 
14, OX19/52-labeled cells were positioned midway between the endothelium and adventitial 
limiting plate. Although volume density measurements from days 15 - 21 were decreased, 
OX19/52-labeled cells were dispersed throughout the perivascular space (Figure 9 D). 
Summary 
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lmmunohistochemical analysis and subsequent computerized image analysis of 
antibody-labeled pulmonary perivascular mononuclear cell infiltrates quantified volume density 
fluctuations within 7 out of 10 selected mouse anti-rat monoclonal antibodies. Volume density 
measurements indicated a biphasic class II +, T cell and macrophage mediated response. 
OX6-, OX8-, ED1- and W3/25-labeled mononuclear cells appeared to be adherent to the 
vascular endothelium and were detected during initial perivascular infiltration by day 7. 
Whereas, OX41-, W3/13- and OX19/52-labeled mononuclear cells appeared to be adherent to 
the vascular endothelium on day 10, but were not observed within the perivascular space until 
day 14. 
Discussion 
The present study is the first to determine a phenotypic profile of mononuclear cells 
present within the pulmonary perivascular infiltrates that characterize interstitial pneumonitis and 
occur as a direct result of acute GVHD. We employed immunohistochemical analysis to define 
the phenotypic components of pulmonary perivascular infiltrates within the adult (DA x LEW) F 1 
hybrid rat in the absence of chemotherapy, irradiation, immunosuppressive drugs or overt 
infection. Our data determined that the process of perivascular infiltration was produced 
through a biphasic influx of OX6+, T-cell and macrophage populations. These results have also 
provided indirect evidence that the early infiltration of T-cell subsets may facilitate a route for 
CMV infection. 
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The primary target organs of acute GVHD, such as spleen, lymph nodes, skin, G.I. 
tract, and liver exhibit increases in both MHC class I and class II antigen expression (Korngold 
and Sprent 1990, Lampert et al. 1982, Lever et al. 1986, Breathnach and Katz 1983, McDonald 
1988). As a result of MHC expression, these GVHD-target organs become the primary sites of 
T-cell infiltration. Class II expression is routinely found on cells within the perivascular and 
subpleural spaces of normal murine lung (Skoskiewicz et al. 1985), but does not appear on 
normal rat epithelial or endothelial cells (Romaniuk et al. 1987). In our present study, the 
concurrent perivascular infiltration of cytotoxic and helper T-cell subsets appeared to correlate 
with the presence of MHC class I and class II expression. Furthermore, OX6-labeled 
mononuclear cells within control perivascular spaces appeared to be macrophages which 
increased throughout acute GVHD and preceded T-cell infiltration. In contrast to perivascular 
labeling, OX6 did not label pulmonary endothelium at any time point following GVHD induction. 
A similar absence of class II expression is noted on murine vascular endothelial cells throughout 
rat lung allograft rejection (Romaniuk et al. 1987). The present OX6-labeled 
immunohistochemical data were consistent with this previous study and corroborated our prior 
conclusions that pulmonary histopathology throughout acute GVHD duplicates lung allograft 
rejection and characterizes the lung as an important target organ following allogeneic BMT 
(Workman and Clancy 1994). 
ED1 and OX41 were used to assess the presence of macrophage subsets within 
perivascular infiltrates. Both ED1 + and OX41 + cells appeared to display a preferential affinity for 
the adventitial limiting plate which is composed primarily of Type IV collagen \( ousem et al. 
1992). During lung allograft rejection, Type IV collagenase staining is observed on perivascular 
mononuclear cells adjacent to the limiting plate \( ousem et al. 1992). There was a striking 
coincidence between the increased volume density of OX41-labeled cells between days 15 - 21, 
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the position of OX41-labeled cells adjacent to the limiting plate, and subsequent dissolution of 
the limiting plate to produce interstitial pneumonitis. It is possible that ED1-labeled cells may 
release cytokines or collagenase to weaken the extracellular matrix and limiting plate, while 
OX41-labeled mononuclear cells may produce the type IV collagenase required to initiate 
dissolution. Further study is needed to determine why the volume density measurements of 
ED1-labeled cells obtained between days 15 - 21 dropped to day 10 values while volume 
density measurements for OX41-labeled mononuclear cells increased 2-fold over day 14 values. 
The presence of OX41-labeled cells during peak volume density values for ED1-labeled cells 
suggested that two different macrophage populations were being labeled by ED1 and OX41 
antibodies. 
OX8, W3/13, W3/25 and OX19/52 antibodies were used to assess the presence of 
T-cell subsets within perivascular infiltrates. oxs+ and W3/25+ cells were both observed within 
perivascular infiltrates on day 7. Volume density measurements exhibited similar rates of 
increase within OX8 and W3/25 antibody-labeled populations between days 7 and 10, as well 
as similar rates of volume density decrease between days 14 and 15 - 21. However, OX8 
volume density measurements on days 7 and 10 comprised a higher portion of overall OX8-
staining than W3/25 volume density measurements for the same time points. W3/25 volume 
density measurements produce a similar staining trend to ED1-labeled cells except for high 
values between days 15 - 21. High volume density values for W3/25-labeled cells between 
days 15 - 21 may indicate that a different epitope of OX41-labeled macrophages was 
incorporated into W3/25 labeling. 
Both W3/13 and OX19/52 antibodies labeled intravascular mononuclear cells on day 
10 but neither antibody was observed within perivascular infiltrates until day 14. Similar rates of 
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increase and decrease occurred for volume density measurements obtained from W3/13- as 
well as OX 19/52-labeled perivascular mononuclear cell populations on days 14 and 15 - 21. 
Relative to the volume density measurements within each population, both W3/13 and OX 19/52 
values were reduced by half between days 15 - 21. Although OX19/52-labeling provided 
appropriate pan T-cell staining within spleen tissues, it did not represent the total of perivascular 
T-cell subset labeling in acute GVHD lungs. We believe that either the OX19 and OX52 
receptors may be altered traversing the endothelium, or the strength of OX19/52 staining may 
be organ specific and naturally low within the pulmonary environment. 
OX41-, W3/13- and OX19/52-labeling were observed only on intravascular 
mononuclear cells within day 10 lung tissues. This data suggested that OX41-, W3/13- and 
OX19/52-labeled cell populations were not present in peripheral blood immediately following the 
induction of acute GVHD. Previous acute GVHD studies using this model showed similar 
fluctuations within the lymphoid populations of other GVHD target organs. A significant increase 
in W3/13-labeled T cells occurred within spleen and lymph nodes during the first 7 days after 
GVHD induction (Clancy 1984). Subsequently, W3/13-labeled spleen populations showed a 
significant decrease between days 7 and 21 while a significant increase of W3/13-labeled cells 
occurred within the submandibular glands and periportal areas of the liver (Clancy 1984, Klein, 
Clancy and Stuart 1982, Clancy, Klein and Weddle 1981). Consequently, we believe that 
W3/13-, OX41-, and OX19/52-labeled cells were not apparent within the perivascular space until 
day 14 because prior to infiltration they were localized within the lymphoid compartments of 
spleen and lymph nodes. In contrast, ED1-, OX8- and W3/25-labeled mononuclear cells may 
have remained within the circulating pool of peripheral blood where they were available for 
initiation of perivascular infiltration on day 7. 
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MOM/3F12/F2-, OX12- and OX39-labeling were not found within the perivascular 
space at any time point throughout acute GVHD. However, all three antibodies demonstrated 
appropriate labeling patterns within positive and negative control tissues as well as minimal 
staining within the lung parenchyma. lmmunohistochemical analysis conducted with the 
MOM/3F12/F2 antibody confirmed the absence of neutrophils observed within perivascular 
infiltrates during histological examination (Workman and Clancy 1994). B cells were not 
present within perivascular infiltrates and none were observed after OX12-labeling. One to 
three OX39-labeled cells were found within each whole lobe lung section, but OX39-labeled 
cells were not observed within perivascular infiltrates at any time point following injection. It is 
possible that the affinity of OX39 for the IL-2r may be altered within the pulmonary environment 
for unknown reasons, or IL-2 may not play a role in the pulmonary histopathology of acute 
GVHD. A noticeable lack of cellular proliferation as determined by the absence of mitotic 
figures also suggested that IL-2 may not act locally during the pathogenesis of acute pulmonary 
GVHD. 
The affinity/adherence of intravascular mononuclear cells to the vascular 
endothelium marks the onset of perivascular infiltration as a direct result of acute GVHD and is 
critical to the eventual development of interstitial pneumonitis. We believe that the 
affinity/adherence of mononuclear cells to the vascular endothelium is induced by the presence 
of activated intravascular donor cells. These activated cells produce increased levels of 
cytokines such as IFN-y, TNF-a., IL-1 (Springer 1990, Duquesnoy, Trager and Zeevi 1991) and 
IL-4 that induce class II expression, upregulate endothelial adhesion molecules and augment 
the development of GVHD (Thornhill et al. 1991, Huchet et al. 1993, Piguet et al. 1989, Clancy, 
Goral and Kovacs 1990, Pober et al. 1986). Activated Th 1 cells are known to release IFN-y 
which increases class II expression, TNF-a. production by macrophages, and the upregulation of 
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ICAM-1 (Duquesnoy, Trager and Zeevi 1991). TNF-a in combination with IFN-y and IL-4 plays 
a principal role in the recruitment of a predominantly mononuclear infiltrate across the vascular 
endothelium through LFA-1/ICAM-1 mechanisms (Thornhill et al. 1991). lmmunohistochemical 
studies on frozen sections from rejecting lung allografts reveal an intense staining pattern of 
TNF-a within pulmonary interstitial mononuclear cells during a period of rejection that duplicates 
the histopathology observed on day 14 of our GVHD model (DeMeester et al. 1993, Workman 
and Clancy 1994). In addition, IFN-y and TNF-a induce upregulation of adhesion molecules 
such as ICAM-1 which also coincides with the mononuclear cell infiltration of other GVHD 
affected organs (Dustin et al. 1988, Norton et al. 1991, Norton and Sloane 1991 ). Previous 
studies have documented that antibodies to IFN-y and TNF-a significantly abrogate the 
histopathology of GVHD-induced skin and intestinal lesions (Piguet et al. 1987, Mowat 1989) as 
well as the perivascular mononuclear infiltration of rejecting lung allografts (DeMeester et al. 
1993). 
In addition to the expression of LFA-1, activated T cells also express VLA adhesion 
molecules which mediate the interaction between lymphocytes that have crossed the 
endothelium and components of the extracellular matrix (Springer 1990). VLA antigens may 
have played a role in positioning early OX8-, W325-, W3/13- and OX19/52-labeled T cells 
midway between the endothelium and adventitial limiting plate, while early ED1- and OX41-
labeled macrophage subsets were found adjacent to the limiting plate. 
In the present study we have been careful to avoid contamination by CMV which is 
symptomatic in 50 - 80% of allogeneic BMT patients and incurrs a mortality rate of 80 - 90% as 
a result of interstitial pneumonitis (Meyers, Flournoy and Thomas 1980, Paulin et al. 1986, 
Neiman et al. 1977, Bartin et al. 1982). Yet, after comparing our results to the data obtained in 
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other acute GVHD studies, a strong correlation emerged between the OX8+, W3/25+ T-cell 
subsets integral to the development of GVHD-induced interstitial pneumonitis and the donor Lyt 
2+ and L3T4+ T-cell subsets required to produce a CMV-induced pneumonitis (Shanley et al. 
1987). 
It is possible that the upregulation of LFA-1/ICAM-1 and VLA adhesion pathways on 
activated T cells which are required to produce a GVHD-induced interstitial pneumonitis may 
also facilitate a route of CMV infection. ICAM-1 acts as a ligand for several viruses such as 
rhinovirus and some strains of coxsackie virus (Greve et al. 1989, Martin et al. 1990). Although 
rhinoviruses have evolved into more than 100 non-crossreactive antigenic variants, 90% bind to 
ICAM-1(Springer 1990). LFA-1 molecules on activated T cells and rhinoviruses both bind to 
overlapping yet distinct regions of the first immunoglobulin-like domain of ICAM-1 (Greve et al. 
1989, Martin et al. 1990, Staunton et al. 1990, Staunton et al. 1989). Therefore, we 
hypothesize that the release of cytokines by activated donor T cells and the subsequent 
upregulation of adhesion molecules may attract latent CMV particles to form a CMV/T-
cell/ICAM-1 complex (studies in progress). The ensuing perivascular infiltration of CMV and 
activated donor T cells may explain the difficulty in distinguishing between the onset of acute 
GVHD and CMV pneumonitis. 
The present study has shown that the perivascular infiltration characteristic of 
interstitial pneumonitis occurrs as a biphasic influx of oxs+, ED1+, OX8+ and W3/25+ 
mononuclear cells on day 7, as well as OX41+, W313+, and OX19/52+ populations on day 14. 
The release of cytokines and collagenase by these perivascular mononuclear cells may help to 
weaken the adventitial matrix and facilitate dissolution of the perivascular limiting plate. Early 
immunohistochemical analysis of transbronchial biopsies may help to diagnosis the onset of 
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GVHD prior to the development of clinical symptoms. 
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Table 20. - - Monoclonal mouse anti-rat antibodies, dilutions, target cells and LUT 
(Look-up Table) lower limit values used for immunohistochemical Image Analysis 
of lung perivascular mononuclear infiltrates throughout acute GVHD 
mAbs Dilution Target Cells LUT Value 
MRC OX-6 1 :150 MHC class II (la) 163 
MRC OX-8 1 :150 Cytotoxic/Suppressor T cells 182 
MRC OX-12 1 :110,000 lgG Kappa Chain N.Q* 
MRC OX-19/52 1 :150 Pan T cells 190 
MRC OX-39 1 :150 IL-2r on activated T cells N.Q* 
MRC OX-41 1: 5,000 Alveolar/activated macrophages 190 
ED1 1 :150 Macrophages/monocytes 179 
W3/25 1 :150 T helper/macrophages 169 
W3/13 1: 2,500 T cells/NK cells 194 
MOM/3F12/F2 1:10,000 Granulocytes N.Q* 
*N.Q - No quantifiable antibody labeling occurred within the perivascular space 
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FIGURE 8. Photomicrographs representative of immunohistochemical labeling 
within the perivascular adventitial spaces of lung tissues throughout acute GVHD. (A) OX6-
labeled mononuclear cell within control tissues (bar indicates 20 µm scale); (B) OX6-labeled 
mononuclear cells within the advanced stages of day 14 perivascular infiltration (bar indicates 
30 µm scale); (C) ED1-labeled mononuclear cells within the early stages of day 14 perivascular 
infiltration (bar indicates 20 µm scale); (D) OX41-labeled mononuclear cells within the early 
stages of perivascular infiltration between days 15-21 (bar indicates 20 µm scale). 
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FIGURE 9. Photomicrographs representative of immunohistochemical labeling 
within the perivascular adventitial spaces of lung tissues throughout acute GVHD. (A) OX8-
labeled mononuclear cell within the early stages of day 14 perivascular infiltration (bar indicates 
30 µm scale); (B) W3/13-labeled mononuclear cells within the perivascular infiltration 
characteristic of day 14 (bar indicates 20 µm scale); (C) W3/25-labeled mononuclear cells within 
the perivascular infiltration characteristic of day 14 (bar indicates 20 µm scale); (D) OX19/52-
labeled mononuclear cells within the early stages of day 14 perivascular infiltration (bar 
indicates 20 µm scale). 
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FIGURE 10. (A) Perivascular infiltrate volume density of OX-6-labeled mononuclear 
cells in noninjected (DAxLEW) F1 controls (day 0), and DAIF1 GVHD-induced, nonirradiated 
adult rats 3, 7, 10, 14, and 15-21 days following injection. Data were obtained using 
quantitative image analysis. Error bars represent means± SEM. Statistical analyses were 
conducted using one-way ANOVA and Tukey post-hoc testing. (*) Control volume density 
measurements were increased over day 3 values because minimal control perivascular spaces 
contained 1-3 OX6-stained cells. Day 3 values were lower than control volume density 
measurements because the number of OX6-labeled cells remained at control values, but there 
was an overall increase in perivascular volume (•)=Ps0.05 and (••)=Ps0.01 as compared to 
control values. N=4 animals per time point. 480 tissue sites were assessed for quantitation. 
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FIGURE 11. Perivascular infiltrate volume density of (A) ED1- and (8) OX41-
stained mononuclear cells in noninjected (DAxLEW) F1 controls (day 0), and DA/F1 GVHD-
induced, nonirradiated adult rats 3, 7, 10, 14, and 15-21 days following injection. Data were 
obtained using quantitative image analysis. Error bars represent means± SEM. Statistical 
analyses were conducted using a one-way ANOVA and Tukey post-hoc testing. (A) ED1-labeled 
cells were not observed within the perivascular spaces of control or day 3 tissues (••)=Ps0.01 
as compared to day 7 values. (8) OX41-labeled cells were not observed within the perivascular 
spaces of control, 3, 7, and 10 day tissues N=4 animals per time point. 480 tissue sites were 
assessed for quantitation. 
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FIGURE 12. Perivascular infiltrate volume density of (A) OX8- and (B) W3/13-
stained mononuclear cells in noninjected (DAxLEW) F1 controls (day 0), and DA/F1 GVHD-
induced, nonirradiated adult rats 3, 7, 10, 14, and 15-21 days following injection. Data were 
obtained using quantitative image analysis. Error bars represent means ± SEM. Statistical 
analyses were conducted using a one-way ANOVA and Tukey post-hoc testing. (A) OX8-
labeled cells were not observed within the perivascular spaces of control or day 3 tissues. 
(•)=P::::,0.05 and (••)=P::::,0.01 as compared to day 7 values. (B) W3/13-labeled cells were not 
observed within the perivascular spaces of control, 3, 7, and 10 day tissues (•)=P::::,0.05 and 
(••)=P::::,0.01 as compared to day 14 values. N=4 animals per time point. 480 tissue sites were 
assessed for quantitation. 
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FIGURE 13. Perivascular infiltrate volume density of (A) W3/25- and (B) OX19/52-
stained mononuclear cells in noninjected (DAxLEW) F1 controls (day 0), and DA/F1 GVHD-
induced, nonirradiated adult rats 3, 7, 10, 14, and 15-21 days following injection. Data were 
obtained using quantitative image analysis. Error bars represent means ± SEM. Statistical 
analyses were conducted using a one-way ANOVA and Tukey post-hoc testing. (A) W3/25-
labeled cells were not observed within the perivascular spaces of control or day 3 tissues 
(•)=Ps0.05 and (••)=Ps0.01 as compared to day 7 values. (B) OX19/52-labeled cells were not 
observed within the perivascular spaces of control, 3, 7, and 10 day tissues (•)=Ps0.05 and 
(••)=Ps0.01 as compared to day 14 values. N=4 animals per time point. 480 tissue sites were 
assessed for quantitation 
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CHAPTER VI 
DISCUSSION 
The studies described within this dissertation have confirmed the original hypothesis 
that the lung is an important target organ of acute lethal GVHD. The experimental designs of 
Chapter's Ill, IV and V were based on a parental ~ F1 model of acute GVHD that omitted the 
influence of irradiation, chemotherapy, immunosuppressive drugs or overt infection. Adult 
(DA x LEW) F 1 hybrid rats were injected with 1 x 106 DA parental lymphoid cells/gram body 
weight which produced 100% morbidity and mortality by day 21. 
The data described in Chapter IV has confirmed the hypothesis that interstitial 
pneumonitis and lymphocytic bronchiolitis/bronchitis occur as direct result of acute GVHD. 
Studies were based on the histological analysis of whole lobe lung sections (4 µm) stained with 
H&E, and the subsequent quantification of variations within alveolar septa! width as well as 
perivascular volume density using light microscopic Image Analysis. Alveolar septa! width and 
perivascular infiltrate volume density values were significantly increased above controls by day 
7, and reached 2.4 and 2.6 fold increases respectively by day 21. Between days 15 - 21, the 
consolidation of perivascular mononuclear cell and alveolar infiltrates marked the onset of 
interstitial pneumonitis. The bronchiolar mononuclear cell infiltrates that characterize 
lymphocytic bronchiolitis/bronchitis were observed around terminal and respiratory bronchioles 
by day 10, fully developed between days 15 - 21, and occurred independently of interstitial 
pneumonitis. Furthermore, the onset of an acute GVHD-induced interstitial pneumonitis 
appeared to describe the "idiopathic pneumonitis" of previously undefined origin. 
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Consequently, Chapter IV produced data that fulfilled several primary objectives of 
this dissertation (see Chapter I, Introduction p. 2). Time course - The pulmonary histopathology 
of acute GVHD was observed by day 7 and became progressively more severe until day 21. 
Anatomical location - The first signs of pathogenesis began in the lung periphery around 
venules as well as arterioles, and advanced to include increasingly larger vessels as well as 
bronchioles between days 15 - 21. Histological progression - Alveolar septal thickening and 
perivascular mononuclear cell infiltration began by day 7, and preceded the onset of 
lymphocytic bronchiolitis during late-stage GVHD. The degree of pulmonary mononuclear 
infiltration and edema observed in Chapter IV was corroborated by an increase in lung cell 
yields as described in Chapter Ill. 
Chapter IV also provided two important insights into the development of acute 
GVHD-induced histopathology. Histological analysis of the data obtained from Chapter IV 
revealed that intravascular mononuclear cells displayed an affinity/adherence for the vascular 
endothelium by day 7. This phenomenon of intravascular adherence occurred prior to 
perivascular infiltration and was most pronounced on days 7 and 10. In addition, the pulmonary 
histopathology produced as a direct result of acute GVHD conformed to the grading system 
applied during the assessment of lung allograft rejection. Consequently, the development of 
interstitial pneumonitis and lymphocytic bronchiolitis/bronchitis that duplicated the histopathology 
of lung allograft rejection provided the first evidence to implicate the lung as a target organ of 
acute GVHD in the adult F 1 hybrid rat. 
Further evidence to implicate the lung as a target organ was supplied by the data 
obtained in Chapter V. This study was based on the immunohistochemical analysis of 
perivascular mononuclear cell infiltrates that characterize interstitial pneumonitis. The 
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phenotypic analysis of perivascular infiltrates conducted in Chapter V fulfilled the last stated 
objective of this dissertation (see Chapter I, Introduction p. 2). Whole left lungs were frozen, 
serially sectioned (4 µm) and incubated with a wide panel of mouse anti-rat monoclonal 
antibodies. The density of labeled antibodies within the perivascular space was quantified by 
light microscopy using Image Analysis software. The data determined that perivascular 
infiltration occurred in a biphasic pattern of first ED1+, OX8+, and W3/25+ cells, then OX41+, 
W3/13+, and OX19/52+ populations. OX6 was expressed in control tissues and during all time 
points throughout acute GVHD. OX12+, OX39+, and MOM/3F12/F2+ cells were not quantifiable 
within perivascular infiltrates at any time point tested. Overall, volume density fluctuations 
occurred within 7 out of the 10 antibodies used. These results indicated that acute GVHD-
induced pulmonary histopathology was a class ii+, T cell and macrophage mediated response. 
Chapter V also determined that OX6, OX8, ED1 and W3/25 antibodies labeled the 
adherent intravascular mononuclear cells observed on day 7 as described in Chapter IV. 
OX41+-, W3/13+- and OX19/52+ - labeled mononuclear cells did not display an affinity/adherence 
for the vascular endothelium until day 10, and were not observed within the perivascular space 
until day 14. The results of Chapter V also showed that OX6+, ED1+, and OX41+ populations 
have a preferential affinity for the perivascular limiting plate which contains a high concentration 
of Type IV collagen. The affinity of mononuclear cells containing Type IV collagenase for the 
limiting plate has suggested a mechanism for dissolution of the limiting plate and onset of 
interstitial pneumonitis. 
Chapters IV and V have also provided indirect evidence to suggest that the 
intravascular affinity/adherence of mononuclear cells is induced by the presence of activated 
intravascular donor T cells that release cytokines which upregulate adhesion molecules. These 
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activated donor cells may be the source of cytokines such as IFN-y, TNF-a, IL-1 and IL-4 that 
induce class II antigen expression, upregulate endothelial adhesion molecules and promote 
perivascular infiltration. The potential upregulation of LFA-1/ICAM-1, ELAM-1, VCAM-1 and 
VLA adhesion molecules may explain the affinity/adherence of intravascular mononuclear cells 
and may be a factor in guiding infiltrated cells to the perivascular limiting plate. 
The compiled data of Chapter's IV and V correlate well to the cutaneous, intestinal 
and hepatic immunopathology of acute GVHD. Each of the 3 primary target organs undergoes 
an increase in class II expression that is accompanied by a mononuclear infiltrate with a high 
proportion of CD8+ T cells. Skin and intestinal tract are also influenced by an increase in IFN-y 
as well as TNF-a, and show an upregulation of ICAM-1, ELAM-1 and VCAM-1. The 
augmentation of pulmonary class W labeling, the early infiltration of OXB+ T cells, the potential 
upregulation of cytokine production, and the observed affinity/adherence of intravascular 
mononuclear cells all appear analogous to the immunopathology that characterizes target 
organs of acute GVHD. Consequently, comparisons between the immunopathology produced 
within lungs and other established target organs also appeared to confirm that the lung is a 
target organ of acute GVHD. 
Future studies should be directed toward: (1) identifying the individual cytokines that 
may be produced by activated intravascular donor T cells, (2) identifying the adhesion 
molecules produced by those cytokines, (3) defining the synergistic relationship between CMV-
induced and GVHD-induced interstitial pneumonitis, and (4) developing a method to detect the 
onset of acute pulmonary GVHD. In situ hybridization would be useful for identifying individual 
cytokines and adhesion molecules. While studies combining the administration of anti-ICAM-1 
and active CMV may determine if a donor T cell/ICAM-1 complex facilitates the transportation of 
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CMV into the privileged perivascular space. In addition, a method needs to be developed that 
can access the lung periphery at multiple tissue sites early after allogeneic BMT. Data from 
Chapter Ill has demonstrated that FACS analysis of BAL cell suspensions can not detect the 
onset or predict the severity of acute GVHD-induced histopathology. 
CHAPTER VII 
SUMMARY 
This dissertation has determined that the lung is an important target organ of acute 
GVHD. Data has been produced to demonstrate that: (1) FACS analysis of BAL cell 
suspensions may be able to suggest an ongoing immune process, but in the absence of 
transbronchial biopsy this method is incapable of determining the onset or progression of acute 
pulmonary GVHD prior to clinical symptoms occurring from the significant deterioration of 
normal pulmonary structure, (2) IP and LB occur as a direct result of acute GVHD, (3) IP 
develops prior to LB and is produced by the coalescence of perivascular and alveolar 
mononuclear cell infiltrates, (4) acute GVHD-induced IP and LB duplicate the histopathology of 
lung allograft rejection, and (5) the process of perivascular infiltration is characterized by a 
biphasic influx of class W, T cell and macrophage populations. 
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